life inspliirvee others live lives fully im blessed jeff julian annual reporton cover jeff julian see jeff 's story patient stories shared annual report depict individual patient responses medicines investigational compounds representative patient responses addition guarantee potential drugs indications still development receive regulatory approval bristolmyers squibb annual report throughout strengthened platform creating value recognizing responsibility shareholders build longterm sustainable growth innovation makes difference today tomorrow giovanni caforio md chief executive officer researcher tiffany kuo working next generation immunotherapy medicinesin every part organization every part world work continued driven unwavering commitment people center everything patients families giovanni caforio md chief executive officer also focused future continuing makes difference today tomorrow advance biopharma strategy initiating throughout every part important operating model evolution aimed organization every part world focusing resources important work continued driven unwavering priorities business commitment people center every year strengthened thing patients families platform creating value recognizing reason focus transformational responsibility shareholders build longterm medicines reason worked harder sustainable growth innovation faster deliver results troper launna bbiuqs sreymlotsirb shareholders important year bristolmyers squibb delivered strong operational financial results expanded indications market performance pd inhibitor opdivo advanced eliquis towards leadership prevention stroke patients atrial fibrillation advanced broad deep portfolio pipeline opportunities immunooncology core specialty therapeutic areas cardiovascular fibrosis immunoscience continued work underserved communities make healthcare accessible need global sales region united states rest world includes japan europethese accomplishments represent latest string impressive leadership milestones achieved eliquis delivering today two years includes new indication head neck cancer respect overall operating achieved late year well performance outstanding year bladder cancer achieved early exceeded budget targets deliv also saw opdivo grow outside ered billion revenue growth us significant regulatory approvals preceding year due european union japan us doubledigit growth number key markets across much portfolio beyond immunooncology key total prescriptions indications growth drivers strong results result strong operating per specialties included anticoagulant eliquis among novel anti formance achieved gaap eps coagulants noacs delivered billion sales nongaap eps newtobrand increase previous year eliquis represents growth prescriptions become leading oral anticoagulant indications vs previous year respectively specialties among globally stroke prevention patients oral anticoagulants much success driven atrial fibrillation us including warfarin strength immunooncology established leadership eliquis reached portfolio revenues nearly billion cardiology terms number total hospitalinstitutional sales among noacs opdivo sales reached billion result prescriptions surpassing warfarin strong uptake across tumor types longtime standard care additionally yervoy sales us started grow made good progress overall global markets due adoption combina market includes primary care yearover year growth tion regimen melanoma physicians across indications tackling hardesttotreat cancers orencia sprycel performed well approved countries challenging saw firsthand experienced doubledigit worldwide last august negative outcome growth billion billion checkmate opdivo monotherapy sales respectively clinical trial st line lung cancer estimated company partner ono also integrated important lessons learned secured important patent litigation trial broad development settlement signing global license program lung cancer believe agreement settle patentinfringe medicines continue play ment litigation related mercks pd people important role improving treatment antibody keytruda pembrolizumab treated outcomes deadly disease settlement critical milestone eliquis worldwide generally broadened bristolmyers squibb protecting since launch label opdivo approved intellectual property rights early us indications six tumor innovators science pd key types unprecedented accomplishment mechanism immunooncology bristolmyers squibb annual report delivering numbers billion revenue proven transformational impact cancer care continue assert intellectual property rights important field defend scientific discoveries delivering tomorrow growth vs throughout year also focused efforts building future clear work develop enhance promising pipeline transformational medicines towards end year started see data next wave pipeline immunooncology three new assets potentially entering registrational studies opdivo addition expect dozen data readouts spanning billion multiple tumor types could broaden label opdivo yervoy next couple years eliquis billion lung cancer remains priority bristolmyers squibb made important progress studies combina orencia tion therapies core strategy fact billion several ongoing phase iii combination programs sprycel address urgent need improved treatment options billion patients lung cancer also advanced early pipeline cardiovascular hepatitis c franchise immunoscience fibrosis expect see important billion data readouts beginning programs address winning yervoy areas high unmet medical need heart failure lupus immunooncology billion nonalcoholic steatohepatitis nash many firstinclass molecules potential bestinclass always recognized importance acquiring innovation externally important year new io compounds business development bristolmyers squibb business clinical development development activity continued enhance key disease billion areas focus spanned partnerships academia invested trials rd biotech larger companies acquired cormorant pharmaceuticals broadens companys oncology pipeline focus tumor microenvironment padlock therapeutics expands companys immunoscience tumor types pipeline signed license agreements nitto denko troper launna bbiuqs sreymlotsirb jeff julian competitor coach cancer survivor head coach rose bowl aquatics n't ready says n't ready ten years eighttime dear friends leave family basically kept allamerican university southern repeating cant cant cant family loved ones california usc champion swimmer could n't leave son could n't leave since adolescent jeff julian wife always known takes succeed first doctors gave jeff wife world early january made rocked today kristine little reason hope announcement social media dear oncologist university california friends family loved ones world los angeles medical center mentioned clinical trial rocked today combination therapy two new immunotherapy drugs ipilimumab nivolumab studies combination doctors given diagnosis stage iv therapy treatment lung cancer continuing lung cancer jeff enrolled weeks treatment first nagging pain scans showed tumors shrunk significantly ever since previous summer jeff n't felt right continued shrink substantially smaller lot athletes water lot potential original size lot goals shooting recalls started feeling pains back inspiring others july jeff returned alma mater named xray revealed large mass jeff 's left lung subsequent usc trojans mens womens assistant coach also scans revealed extensive metastases prognosis continues coach son aspiring olympian six months says jeff hardest part says sitting trenton yearold son talk live life inspire others live lives diagnosis fully im blessed jeff says bristolmyers squibb annual report targeted sirna therapy advanced nash psioxus therapeutics armed oncolytic virus address solid tumors collaboration enterome focused microbiomederived biomarkers drug dr alan anderson texas childrens hospital examining cancer patient botswana targets developed therapeutics cancer global hope addressing childhood cancer order ensure resources applied import blood disorders africa ant opportunities company initiated evolution operating model one strengthening ability seize child diagnosed lifethreatening opportunities increasingly challenging environment disease cancer parents cling hope child survive hope often delivering underserved communities disproportionate depending live throughout year continued build execute africa children develop programs help ensure patients access health cancer year vast majority die care including medicines bristolmyers little access diagnostic squibb foundation promoted health equity better treatment services stark contrast health outcomes people around world highincome countries percent patient assistance programs provided medicines pediatric cancer patients survive patients financial challenges led bristolmyers squibb foundations taken together commitment access focused secure future program global populations need global scope included hope hematologyoncology pediatric excellence hiv cancer africa well hepatitis c asia initiative address lack diagnosis treat included cancer care vulnerable populations ment care pediatric hematologyoncology well mental health care veterans us southern eastern africa commitment included several programs including together texas childrens cancer help patients need temporary help paying hematology centers baylor college medication medicine international pediatric aids initiative commitment good citizenship extended beyond texas childrens hospital bristolmyers squibb initiatives continued work united foundation partner governments nations global compact well go green activi botswana malawi uganda develop com ties bristolmyers squibb sites promote sustainability prehensive treatment network provide financial inkind resources program provided disaster relief support affected populations haiti ecuador japan joined white house combined grant million moonshot initiative share goal accelerating new group work next five years help treatments eventually finding cure cancer create innovative pediatric hematologyoncology treatment network help build longterm also put place exciting new initiative provide capacity treat dramatically improve cancer care children subsaharan africa formally prognosis thousands children blood dis orders cancer southern eastern africa troper launna bbiuqs sreymlotsirb kt jones finding purpose cancer diagnosis kt jones getting fitted tuxedo nearly years battling hodgkin wedding noticed bow tie thought lymphoma one treatment another wasnt cooperating oncologist told kt life getting ready months live better get couldnt get tie straight recalled affairs order rather tell every time adjusted tie would always begin come wife grim news kt got determined slightly slanted end countless hours research noticed lump neck internet kts perseverance led though thought pulled muscle clinical trial nivolumab gym day kt visited nearby hospital physician examined lump didnt continue push would never found told biopsy soon got home kt recalled hammered fight honeymoon got clinical trial shortly celebrating marriage wife kristine kt soon started feel better health improved tests revealed kt hodgkin lymphoma nearly four years later kts latest tests detect cancer kristine enjoy quality time together hes thought life getting ready begin come taken walking every day hes followed artistic end said next decade kt juggled family passion becoming freelance photographer life work chemotherapy treatments ultimately heartbreaking news cancer recurred hes also filled new sense purpose id good results shortly stopping treatments know people fighting cancer ive cancer would start grow said kt lives helped find clinical trials kt said thats purpose delaware didnt option keep trying bristolmyers squibb annual report achievements selection awards recognitions launched global hope looking forward firstofitskind pediatric hematology ranked among top look ahead excited oncology treatment network one corporate responsibility tremendous opportunities magazines list designed develop capacity advance science continue best corporate citizens infrastructure treat dramatically making difference lives th consecutive year improve prognosis outcomes patients families thousands children cancer important work deliver southern eastern africa longterm value shareholders strengthening company appointment dr thomas lynch recognized forbes one jr chief scientific officer culture americas best employers important step evolution employees committed throughout past year contin mission discover develop company transitions next phase deliver innovative medicines ued focus people growth tom brings unique perspec help patients prevail make possible extraordinary tive business deep serious diseases colleagues around world experience clinical researcher leader large research centers practicing placed increased priority physician fortunate making sure experience leading rd organization bristolmyers squibb employees honored national gay engaging challenging rewarding building progress lesbian chamber commerce increased focus diversity well positioned navigate collaboration creating powerfully inclusive work increasing complexity competi partners national business tiveness industry including inclusion consortium top experience launched new global bestofthebest company people business resource groups important conversations pricing access continue pbrgs evolution us draw energy vision diversity based employee resource groups workforce discover develop leverage employees business deliver transformational medicines insights diverse perspectives continue advanced workplace initiative working mother make sure patients making significant physical changes best companies th regardless circumstances consecutive year buildings offices create even access quality healthcare company made list energizing collaborative work company recognized environment onand nearsite childcare options full benefit eligibility bristolmyers squibb people competitive advantage throughout continued giovanni caforio md chief executive officer celebrate strengthen fact march troper launna bbiuqs sreymlotsirb believe strength science best people business position us well continue delivering innovation make difference lives patients lamberto andreotti chairman message chairman board retire board directors nearly past two years giovanni continued evolve years company reflecting company confident well positioned significant transformation bristolmyers squibb longterm growth today highly focused undergone become leading biopharma company known transformational medicines core therapeutic areas innovation focus patients become oncology cardiovascular fibrosis immunoscience company known leading scientific discoveries inno innovationbased industry unique challenges vative medicines focused challenging diseases risks experienced recent past continue evolve change today knowing believe strength science best must sustain platform longterm value creation people business position us well continue delivering joined bristolmyers squibb wanted innovation makes difference lives patients work company making difference peoples better example addition lives particularly struggling cancer decade dr thomas lynch jr companys new chief scientific later given extraordinary opportunity lead officer experience focus patients career company take company next level help makes right choice lead rd organization reach potential closing also want welcome three new became chief executive officer pivotal exciting directors recently joined companys board time bristolmyers squibb made bob bertolini matt emmens ted samuels way period adjustment midst brings company important experience skills biopharma transformation faced unprecedented strengthen complement board challenges opportunities transformed bristol myers squibb better compete everchanging bristolmyers squibb continues evolve grow external environment focus patients people continue set us apart proud company without question rose challenges seized excited future opportunities stepped ceo bristolmyers squibb widely recognized pioneering thank promising field immunooncology increasingly diversified portfolio innovative medicines lamberto andreotti chairman delivering strong shareholder return march bristolmyers squibb annual report bristolmyers squibb development pipeline oncology phase phase ii phase iii approved indications glypican adc opdivo opdivo opdivo hepatocellular carcinoma nonhodgkin lymphoma adjuvant melanoma previously treated follicular lymphoma metastatic melanoma antitigit nd line small cell solid tumors nonhodgkin lymphoma lung cancer st line braf wildtype diffuse large bcell metastatic melanoma antigitr unresectable nonsmall lymphoma solid tumors cell lung cancer melanoma across braf status msi colon cabiralizumab st line head neck previously treated metastatic solid tumors ovarian squamous nonsmall cell rd line gastric lung cancer anticd nd line hepatocellular st line glioblastoma solid tumors carcinoma previously treated metastatic nd line glioblastoma nonsquamous nonsmall cell antiox cns lymphoma lung cancer solid tumors st line hepatocellular antilag opdivo carcinoma previously treated advanced antilag solid tumors renal cell carcinoma solid tumors lirilumab adjuvant bladder hematologic malignancies advanced hodgkin hematologic malignancies nd line esophageal lymphoma ido inhibitor urelumab opdivo adjuvant esophageal solid tumors previously treated metastatic solid tumors gastroesophageal head neck cancer mesothelinadc hematologic malignancies opdivo yervoy solid tumors previously treated metastatic antifucosyl gm st line nonsmall urothelial carcinoma humaxil small cell lung cancer cell lung cancer solid tumors opdivo yervoy empliciti st line small cell antiher st line multiple myeloma lung cancer braf wildtype metastatic melanoma breast cancer pomalidomide combo st line renal cell melanoma across braf status bet inhibitor yervoy carcinoma solid tumors adolescent melanoma yervoy st line head neck metastatic melanoma ulocuplumab sprycel st line gastric hematologic malignancies pediatric adjuvant melanoma st line esophageal lirilumab empliciti solid tumors st line mesothelioma relapsedrefractory multiple myeloma revlimid combo lirilumab empliciti opdivo empliciti multiple myeloma multiple myeloma sprycel st line chronic urelumab empliciti empliciti myelogenous leukemia multiple myeloma st line multiple myeloma revlimid combo refractory chronic opdivo solid tumors prostvac myelogenous leukemia hematologic malignancies metastatic castration resistant prostate cancer opdivo yervoy solid tumors opdivo pediatric note pipeline excludes clinical collaborations evelopment partnership empliciti abbvie sprycel otsuka opdivo yervoy ono pharmaceutical collaboration ono also includes early stage compounds prostvac bavarian nordic lirilumab innate pharma antiher fstar alpha ltd cabiralizumab five prime therapeutics eliquis pfizer galectin inhibitor galecto biotech ab pentraxin promedior hsp nitto denko corporation trials exploring various combinations partnerrun study option rights troper launna bbiuqs sreymlotsirb bristolmyers squibb development pipeline immunoscience phase phase ii phase iii approved indications tyk inhibitor lulizumab orencia orencia autoimmune diseases lupus lupus nephritis rheumatoid arthritis intravenous pdl inhibitor btk inhibitor psoriatic arthritis autoimmune diseases rheumatoid arthritis rheumatoid arthritis sjogrens syndrome subcutaneous btk max anticdl nulojix rheumatoid arthritis autoimmune disease switch cni rheumatoid arthritis auto injector sp tyk inhibitor renal transplant autoimmune diseases psoriasis juvenile idiopathic arthritis antiip early rheumatoid arthritis ulcerative colitis nulojix antipdl de novo renal transplant sepsis opdivo sepsis cardiovascular phase phase ii phase iii approved indications factor xia inhibitor nitroxyl donor eliquis eliquis vte prevention thrombosis heart failure pediatric vte treatment orthopedic surgery par antagonist stroke prevention thrombosisstroke atrial fibrillation vte treatment fibrotic diseases genetically defined diseases phase phase ii phase galectin inhibtor lpa antagonist antimyostatin idiopathic fibrosis duchenne muscular dystrophy pulmonary fibrosis pegfgf antietau pegfgf fibrosis progressive supranuclear palsy fibrosis pentraxin hsp myelofibrosis fibrosis idiopathic pulmonary fibrosis data january approved fda february bristolmyers squibb annual report dagmar enjoying lifes simple pleasures dagmar vibrant dynamic receiving news cancer personality shares front cancer equal death returned brought back live studio audience cohost emotions first diagnosis cancer equals fight successful weekday talk show except time dagmar knew da da con raymond dagmar questions ask fight puerto rico afraid know survival dagmar experienced way hope way persistent soreness throat first attributed forward survived said dagmar line work time dagmar knew listen body go doctor biopsy discovered surgery lungs dagmars oncologist recommended head neck cancer opdivo dagmar began treatment june returned routine way life including reprising role dagmar would remain away cameras several months cohost da da fda approved opdivo receive chemotherapy radiation pain worry treatment patients recurrent metastatic unknown dagmar remained hopeful focused time squamous cell carcinoma head neck disease lifes simple pleasures especially walks beach progression platinumbased therapy diagnosed cancer appreciation little moments life walking beach hearing today dagmar uses experience platform encourage waves feeling salt water putting feet cancer never give important sand became beautiful moments said dagmar thing patient hold onto belief possible dagmar returned work thought worst door open see right behind however scan showed cancer tell door metastasized dagmars lung go said dagmar troper launna bbiuqs sreymlotsirb bristolmyers squibb financial report managements discussion analysis financial condition results operations quantitative qualitative disclosures market risk consolidated financial statements notes consolidated financial statements reports management controls procedures reports independent registered public accounting firm performance graph fiveyear financial summary summary abbreviated terms fin p ccindd pmbristolmyers squibb managements discussion analysis financial condition results operations executive summary bristolmyers squibb company global specialty biopharmaceutical company whose mission discover develop deliver innovative medicines help patients prevail serious diseases refer summary abbreviated terms end annual report terms used throughout document received approvals new medicines additional indications formulations currently marketed medicines major markets us eu japan well announced multiple regulatory milestone achievements opdivo also encountered significant setback firstline lung cancer announcement negative results checkmate announced would pursue accelerated regulatory pathway opdivoyervoy combination therapy firstline lung cancer pursuing broad program firstline lung cancer encompassing combinations opdivoyervoy opdivo chemotherapy opdivo combined yervoy chemotherapy also committed investigating opdivo combination yervoy anticancer agents tumor types continue believe breadth depth io portfolio positions us well future new io compounds clinical development trials across different tumor types october announced evolution operating model discussed strategy revenues increased result higher opdivo eliquis orencia product sales impacts partially offset expiration us commercialization rights abilify transfer erbitux rights north america increased competition reyataz sustiva baraclude certain markets increase gaap eps due higher revenues divestiture gains royalties lower rd license asset acquisition charges partially offset higher eliquis profit sharing opdivo related expenses tax impact specified items earnings mix contributed change effective tax rate adjusting divestiture gains rd license asset acquisition charges specified items nongaap eps increased highlights following table summarizes financial information year ended december dollars millions except per share data total revenues total expenses earnings income taxes provision income taxes effective tax rate net earnings attributable bms gaap nongaap diluted earnings per share gaap nongaap cash cash equivalents marketable securities nongaap financial measures including nongaap earnings related eps information adjusted exclude specified items represent certain costs expenses gains losses items impacting comparability financial results detailed listing specified items information reconciliations nongaap financial measures refer nongaap financial measures annual report significant product pipeline approvals following summary significant approvals received product date approval jmhlw manufacturing marketing approval treatment relapsed refractory december chl received alliance partner ono ec approval treatment adult patients relapsed refractory chl asct november treatment brentuximab vedotin fda approval treatment patients scchn disease progression november platinumbased therapy jmhlw manufacturing marketing approval treatment unresectable opdivo august metastatic rcc received alliance partner ono fda approval treatment patients chl relapsed progressed may autohsct posttransplantation brentuximab vedotin april ec approval treatment previously treated rcc april ec approval treatment previously treated patients metastatic nsq nsclc jmhlw manufacturing marketing approval treatment previously untreated february unresectable melanoma ec approval treatment unresectable metastatic melanoma regardless braf may opdivo mutational status yervoy fda expanded use treatment previously untreated unresectable metastatic january melanoma regardless braf mutational status jmhlw manufacturing marketing approval combination revlimid september dexamethasone treatment multiple myeloma empliciti ec approval treatment multiple myeloma combination therapy revlimid may dexamethasone patients received least one prior therapy ec approval combination mtx treatment highly active progressive september disease adult patients ra previously treated mtx announced us commercial launch orencia clickject autoinjector new self orencia july administered autoinjector adults moderate severe ra announced commercial launch japan orencia clickject autoinjector adults may moderate severe ra jmhlw manufacturing marketing approval ximency combination tablet december contains daclatasvir asunaprevir beclabuvir treatment hcv genotype hepatitis c fda approval daklinza use sofosbuvir treatment chronic hcv february franchise genotypes three additional patient populations ec approval daklinza use sofosbuvir treatment chronic hcv three january new patient populations ec approval reyataz oral powder indicated hivinfected children least months reyataz june kg optimized reyataz capsule pediatric dosing recommendations refer product pipeline developments developments marketed products latestage pipeline strategy focus specialty biopharmaceutical company discovering developing delivering transformational medicines address serious unmet medical needs strategy combine resources scale capability pharmaceutical company speed focus innovation biotech industry four strategic priorities drive business performance continue build strong franchise io maintain diversified portfolio within outside io continue disciplined approach capital allocation including establishing partnerships collaborations essential component successfully delivering transformational medicines patients bristolmyers squibb developing new medicines following core therapeutic areas oncology including io immunoscience cardiovascular fibrotic disease gdd io continue invest new studies monotherapy combination therapy new molecules mechanisms action delivering promising new treatment options patients lung cancer quickly possible continues priority company continue invest significantly deep pipeline innovative medicines covering broad array cancers entered several collaboration agreements research develop opdivo approved investigational oncology agents combination regimens including yervoy remain focused wellresourced firstline lung development programs continuously look ways strengthen broad portfolio bring forward new treatments beyond cancer continue strengthen early stage portfolio immunoscience cardiovascular fibrotic diseases internally partnerships diverse group companies academic institutions new expanded research activities believe internal external focus differentiated contributes transformation portfolio commercial model continues evolve marketed product portfolio growing manner consistent overall strategy continue drive growth opdivo expanding additional indications tumor types monotherapy combination yervoy anticancer agents beyond opdivo yervoy building continued success remain strongly committed eliquis orencia sprycel commercial infrastructure uniquely leveraged potential growth announced plans multiyear evolution operating model focusing commercial rd resources key brands markets delivering leaner administrative functions streamlining manufacturing network reflect importance biologics current future portfolio new operating model enable us deliver strategic financial operational flexibility necessary invest highest priorities looking ahead continue implement biopharma strategy driving growth key brands executing product launches investing diverse innovative pipeline including business development focusing prioritized markets increasing investments biologics manufacturing capabilities maintaining culture continuous improvement acquisition licensing arrangements acquisition licensing transactions allow us focus resources behind growth opportunities drive greatest longterm value focused following core therapeutic areas oncology including io immunoscience cardiovascular fibrotic diseases significant transactions entered summarized nitto denko december bms nitto denko entered exclusive worldwide license agreement granting bms right develop commercialize nitto denko 's investigational sirna molecules targeting hsp vitamin containing formulations includes nitto denko 's lead asset ndls currently phase ib study treatment advanced liver fibrosis agreement also grants bms option receive exclusive licenses hsp sirnas vitamin containing formulations treatment lung fibrosis organ fibrosis cormorant july bms acquired outstanding shares cormorant private pharmaceutical company focused development therapies cancer rare diseases acquisition provides bms full rights cormorant 's lead candidate humaxil phase iii monoclonal antibody represents potentially complementary io mechanism action tcell directed antibodies costimulatory molecules padlock april bms acquired outstanding shares padlock private biotechnology company dedicated creating new medicines treat destructive autoimmune diseases acquisition provides bms full rights padlocks pad inhibitor discovery program focused development potentially transformational treatment approaches patients rheumatoid arthritis padlocks pad discovery program may additional utility treating systemic lupus erythematosus autoimmune diseases portola february bms pfizer entered collaboration license agreement portola develop commercialize investigational agent andexanet alfa japan andexanet alfa designed reverse anticoagulant activity factor xa inhibitors including eliquis bms pfizer responsible development regulatory activities andexanet alfa japan exclusively commercializing agent japan portola retains rights andexanet alfa outside japan responsible manufacturing supply addition transactions bms provided notice terminations california institute biomedical research pertaining research collaboration agreement development antifibrotic preclinical compounds dual therapeutics llc pertaining research collaboration agreement development anticancer preclinical compounds annual report results operations regional revenues composition changes revenues follows year ended december vs vs total revenues analysis change analysis change total foreign total foreign dollars millions change exchangeb change exchangeb united states europe rest world othera na na total revenues include royalties alliancerelated revenues products sold regional commercial organizations b foreign exchange impacts derived applying prior period average currency rates current period sales increase us revenues resulted higher demand opdivo eliquis daklinza partially offset full year impact expirationtransfer commercialization rights abilify erbitux average us net selling prices increased approximately chargebacks rebates discounts refer product revenues commentary additional information increase us revenues resulted launch opdivo daklinza higher demand eliquis sprycel partially offset partial year impact expirationtransfer commercialization rights abilify erbitux average us net selling prices increased approximately chargebacks rebates discounts increase europe revenues resulted higher demand opdivo eliquis partially offset lower demand yervoy europe revenues included recognition approximately million previously deferred daklinza revenue france decrease europe revenues resulted unfavorable foreign exchange expiration commercialization rights abilify eu june partially offset launch daklinza certain eu countries third quarter higher demand eliquis europe revenues also impacted recognition previously deferred daklinza revenue france decrease rest world revenues resulted increased competition hepatitis c franchise japan unfavorable foreign exchange primarily latin america partially offset higher demand opdivo eliquis increase rest world revenues resulted launch daklinza sunvepra dual regimen japan third quarter higher demand eliquis partially offset unfavorable foreign exchange primarily japan decrease revenues resulted expiration certain supply arrangements decrease revenues resulted expirationtransfer certain licensing royalty rights refer item financial statementsnote alliances discussion alliances single country outside us contributed total revenues except japan contributed total revenues bristolmyers squibb grosstonet adjustments recognize revenue net grosstonet adjustments described critical accounting policies share certain abilify atripla revenues reflected net grosstonet adjustments alliance revenues although presented grosstonet adjustment tables share abilify atripla grosstonet adjustments approximately million billion billion grosstonet adjustments decreased due expiration us commercialization rights abilify april activities ending reserve balances significant category grosstonet adjustments follows rebates chargebacks medicaid returns discounts dollars millions cash discounts medicare rebates adjustments total balance january provision related sale made current period prior period returns payments foreign currency translation balance december provision related sale made current period prior period returns payments foreign currency translation balance december reconciliation gross product sales net product sales significant category grosstonet adjustments follows excluding alliance revenues abilify atripla year ended december change dollars millions vs vs gross product sales grosstonet adjustments chargebacks cash discounts medicaid medicare rebates rebates returns discounts adjustments total grosstonet adjustments net product sales changes grosstonet adjustments primarily function changes sales volume payer channel mix contractual legislative discounts rebates grosstonet adjustments increased higher rate gross product sales primarily increasing mix us versus international gross product sales adjustments much higher chargebacks cash discounts increased periods primarily due higher eliquis opdivo product sales us medicaid medicare rebates increased periods primarily due higher eliquis product sales us rebates returns discounts adjustments increased primarily due higher worldwide sales eliquis opdivo increased due higher sales eliquis additional rebates daklinza approximately million amounts previously deferred france annual report product revenues year ended december change dollars millions vs vs oncology empliciti elotuzumab na us na nonus na na erbitux cetuximab us nonus opdivo nivolumab us nonus sprycel dasatinib us nonus yervoy ipilimumab us nonus cardiovascular eliquis apixaban us nonus immunoscience orencia abatacept us nonus virology baraclude entecavir us nonus hepatitis c franchise daclatasvir asunaprevir us na nonus reyataz atazanavir sulfate franchise us nonus sustiva efavirenz franchise us nonus neuroscience abilify aripiprazole us nonus mature products us nonus change excess bristolmyers squibb empliciti humanized monoclonal antibody treatment multiple myeloma empliciti launched us december eu may japan september erbitux monoclonal antibody treatment certain types metastatic colorectal cancer scchn bms transferred rights erbitux north america lilly october refer item financial statementsnote alliances discussion opdivo fully human monoclonal antibody binds pd nkt cells approved continues investigated anticancer treatment refer significant product pipeline approvals discussion opdivo approvals us international revenues increased periods due higher demand resulting rapid commercial acceptance several indications including melanoma head neck lung kidney blood cancer expect competition increase sprycel oral inhibitor multiple tyrosine kinase indicated firstline treatment adults philadelphia chromosome positive chronic myeloid leukemia chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate us revenues increased periods due higher average net selling prices demand international revenues increased due higher demand international revenues decreased due unfavorable foreign exchange partially offset higher demand may experience decline european revenues second half due unfavorable epo board appeal 's decision yervoy monoclonal antibody treatment patients unresectable metastatic melanoma us revenues increased due higher demand result approvals adjuvant treatment opdivoyervoy regimen patients metastatic melanoma us revenues decreased due lower demand resulting introduction io products used treat patients melanoma including opdivo international revenues decreased due lower demand resulting introduction io products used treat patients melanoma including opdivo international revenues decreased due unfavorable foreign exchange eliquis oral factor xa inhibitor targeted stroke prevention adult patients nonvalvular atrial fibrillation prevention treatment venous thromboembolic disorders us international revenues increased periods due higher demand resulting increased commercial acceptance novel oral anticoagulants market share gains orencia fusion protein indicated adult patients moderate severe active ra also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular juvenile idiopathic arthritis us revenues increased periods due higher average net selling prices demand international revenues increased periods due higher demand partially offset unfavorable foreign exchange baraclude oral antiviral agent treatment chronic hepatitis b us revenues continued decrease periods due loss exclusivity september international revenues decreased following loss exclusivity south korea october international revenues decreased due unfavorable foreign exchange partially offset higher demand certain countries hepatitis c franchise daklinza nsa replication complex inhibitor sunvepra ns protease inhibitor daklinza launched us july international revenues decreased due lower demand resulting increased competition primarily japan international revenues also included recognition approximately million previously deferred daklinza revenue france international revenues increased due higher demand following launch certain eu countries japan third quarter subsequent approvals international markets us international revenues expected significantly decline due lower demand resulting increased competition annual report reyataz franchise includes reyataz protease inhibitor treatment hiv evotaz atazanavir mg cobicistat mg combination therapy containing reyataz tybost us revenues continued decrease periods due lower demand resulting increased competition partially offset higher average net selling prices loss exclusivity reyataz expected december may experience higher decline revenue future periods due generic competition international revenues continued decrease periods due lower demand resulting increased competition unfavorable foreign exchange sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla us revenues continued decrease periods due lower demand resulting increased competition partially offset higher average net selling prices loss exclusivity sustiva expected december may result termination joint venture agreement gilead may reduce revenues beyond international revenues continued decrease periods due sustiva 's loss exclusivity europe november abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder us commercialization rights abilify expired april international revenues decreased periods following expiration eu commercialization rights june otsuka becoming principal end customer sales certain markets mature products includes products including lost exclusivity major markets diabetes alliance products otc brands royalty revenue us revenues decreased due favorable impact sales return reserve reduction plavix million us revenues decreased primarily due diabetes business divestiture february international revenues decreased due expiration certain supply arrangements lower sales due divestiture certain mature products increased competition otc products unfavorable foreign exchange international revenues decreased due expirationtransfer certain licensing royalty rights diabetes business divestiture unfavorable foreign exchange continued generic erosion estimated enduser demand pursuant sec consent order described sec consent order monitor level inventory hand us wholesaler distribution channel outside us direct customer distribution channel obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception estimated levels inventory distribution channel excess one month hand following products material results operations dates indicated us products estimated levels inventory distribution channel excess one month hand december international products estimated levels inventory distribution channel excess one month hand september dafalgan analgesic product sold principally europe months inventory hand internationally direct customers compared months inventory hand june level inventory hand primarily due ordering patterns pharmacists france efferalgan analgesic product sold principally europe months inventory hand internationally direct customers compared months inventory hand june level inventory hand primarily due ordering patterns pharmacists france fervex cold flu product months inventory hand direct customers compared months inventory hand june level inventory hand primarily france support product seasonality perfalgan analgesic product months inventory hand internationally direct customers compared months inventory hand june level inventory hand primarily gulf countries saudi arabia due extended delivery lead time us generally determine months hand estimates using inventory levels product hand amount movement provided three largest wholesalers account approximately total gross sales us products factors may influence estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data may impacted recordkeeping processes bristolmyers squibb nonus businesses significantly direct customers information available direct customer product level inventory corresponding outmovement information reliability thirdparty demand information varies widely limit direct customer sales channel inventory reporting influence demand information exist otherwise available developed variety methodologies estimate data including using historical sales made direct customers third party market research data related prescription trends enduser demand given difficulties inherent estimating thirdparty demand information evaluate methodologies estimate direct customer product level inventory calculate months hand ongoing basis make changes necessary factors may affect estimates include generic competition seasonality products price increases new product launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations information required estimate months hand direct customer distribution channel nonus business year ended december available prior filing annual report disclose product levels inventory excess one month hand expected demand subject de minimis exception next quarterly report form q expenses change dollar millions vs vs cost products sold marketing selling administrative research development incomeexpense total expenses change excess cost products sold cost products sold include material internal labor overhead costs owned manufacturing sites thirdparty processing costs supply chain costs managed global manufacturing supply organization cost products sold also includes royalties profit sharing attributed licensed products alliances foreign currency hedge settlement gains losses amortization acquired developed technology costs business combinations regulatory approval milestones cost products sold typically vary periods result product mix volume particularly resulting royalties profit sharing expenses connection alliances changes foreign currency price inflation costs attributed rationalization manufacturing sites resulting accelerated depreciation impairment charges stranded costs cost products sold increased primarily due higher eliquis profit sharing million lower foreign currency hedge settlement gains higher puerto rico excise tax cost products sold remained relatively flat higher eliquis profit sharing million offset favorable foreign exchange marketing selling administrative marketing selling administrative expenses include salary benefit costs thirdparty professional marketing fees outsourcing fees shipping handling costs advertising product promotion expenses attributed product manufacturing costs research development expenses expenses managed regional commercialization organizations global enabling functions finance legal information technology human resources certain expenses shared alliance partners based upon contractual agreements expenses typically vary periods due new product launch promotional activities marketing selling administrative expenses increased due higher advertising promotion additional sales related activities supporting opdivo partially offset lower spend virology products favorable foreign exchange marketing selling administrative expenses remained relatively flat increased salesrelated activities supporting eliquis opdivo hepatitis c franchise offset favorable foreign exchange million additional expenses related branded prescription drug fee resulting changes irs guidelines annual report research development research development activities include discovery research preclinical clinical development drug formulation well clinical trials medical support marketed products expenses include salary benefit costs thirdparty grants fees paid clinical research organizations supplies upfront contingent milestone payments licensing asset acquisitions investigational compounds iprd impairment charges proportionate allocations enterprisewide costs allocations include facilities information technology employee stock compensation costs appropriate costs certain expenses shared alliance partners based upon contractual agreements expenses typically vary periods number reasons including timing license asset acquisition charges iprd impairment charges research development expenses decreased due lower license asset acquisition charges partially offset acceleration expansion opdivo development programs capabilities lower iprd impairment charges research development expenses increased due higher license asset acquisition charges acceleration expansion opdivo development programs capabilities partially offset lower iprd impairment charges favorable foreign exchange license asset acquisition charges million billion million including million padlock nitto denko flexus cormorant billion flexus cardioxyl five prime million ipierian million milestone paid former shareowners flexus commencement phase clinical trial iprd impairment charges million million million including million lpa antagonist million peginterferon lambda accelerated depreciation million million result expected exit certain rd sites us accelerated depreciation results reduction estimated useful lives related assets site various dates expected approximate million refer item financial statementsnote alliances note acquisitions divestitures note goodwill intangible assets acquisition licensing arrangements nongaap financial measures specified items information incomeexpense income increased billion due higher divestiture gains royalties licensing income lesser extent lower litigation settlements pension debt redemption charges expense decreased million due lower pension charges partially offset lower divestiture gains divestiture gains million million million including certain otc products investigational hiv medicines businesses mount vernon indiana manufacturing facility erbitux ixempra certain mature otc product businesses diabetes business royalties licensing income million million million including contingent consideration erbitux diabetes business divestitures including transfer certain future royalty rights pertaining amylin product sales pension charges million million million including additional pension charge million following purchase group annuity contract prudential insurance company america provision restructuring million million million october company announced evolution operating model drive companys continued success near longterm focused investment commercial opportunities key brands markets competitive agile rd organization accelerate pipeline streamlined operations realigned manufacturing capabilities broaden biologics capabilities reflect current future portfolio new operating model enable company deliver strategic financial operational flexibility necessary invest highest priorities across company restructuring charges approximately million expected incurred actions addition accelerated depreciation impact discussed refer item financial statementsnote acquisitions divestitures note incomeexpense note restructuring note pension postretirement benefit plans information bristolmyers squibb income taxes dollars millions earnings income taxes provision income taxes effective tax rate historically effective income tax rate lower us statutory rate due decision indefinitely reinvest earnings certain manufacturing operations low tax jurisdictions switzerland ireland puerto rico bms operates favorable tax grant puerto rico scheduled expire prior tax impact attributed rd charges divestiture transactions specified items including additional transfer pricing reserves increased effective tax rate reduced effective tax rate tax benefits attributed rd charges padlock flexus cormorant flexus cardioxyl ipierian lower nondeductible goodwill allocated business divestitures higher valuation allowances attributed capital loss carryforwards released impacted effective tax rates minimal income taxes attributed diabetes business divestiture gain capital loss deduction sale amylin shares tax basis differences resulting primarily allocated goodwill amylin deferred taxes unfavorable earnings mix high low tax jurisdictions higher us foreign tax credits resulting puerto rico excise tax periods also impacted effective tax rates refer item financial statementsnote income taxes information comprehensive us tax reform continues discussed proposed including among items changes corporate tax rate border adjustment tax changes us taxes foreign earnings currently uncertain whether changes enacted effective dates comprehensive tax reform occurs financial condition results operations cash flows could significantly impacted however unable determine potential impact time nongaap financial measures nongaap financial measures including nongaap earnings related eps information adjusted exclude certain costs expenses gains losses specified items evaluated individual basis items adjusted considering quantitative qualitative aspects typically one following characteristics highly variable difficult project unusual nature significant results particular period indicative future operating results similar charges gains recognized prior periods likely reoccur future periods including restructuring costs accelerated depreciation impairment property plant equipment intangible assets rd charges connection acquisition licensing third party intellectual property rights divestiture gains losses pension legal contractual settlement charges debt redemption gains losses among items deferred current income taxes attributed items also adjusted considering individual impact overall tax expense deductibility jurisdictional tax rates nongaap information intended portray results baseline performance supplement enhance management analysts investors overall understanding underlying financial performance facilitate comparisons among current past future periods example nongaap earnings eps information indication baseline performance items considered us reflective ongoing results addition information among primary indicators use basis evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information intended considered isolation substitute net earnings diluted eps prepared accordance gaap annual report specified items follows year ended december dollars millions cost products solda additional year branded prescription drug fee process standardization implementation costs marketing selling administrative license asset acquisition charges iprd impairments accelerated depreciation research development provision restructuring litigation settlements divestiture gains royalties licensing income pension charges intangible asset impairment written option adjustment loss debt redemption otherb incomeexpense increase pretax income income taxes items specified tax chargec income taxes increase net earnings specified items cost products sold accelerated depreciation asset impairment shutdown costs b includes million additional year branded prescription drug fee c specified tax charge relates transfer pricing matters reconciliations gaap nongaap follows year ended december dollars millions except per share data net earnings attributable bms used diluted eps calculation gaap specified items net earnings attributable bms used diluted eps calculation nongaap average common shares outstanding diluted diluted eps attributable bms gaap diluted eps attributable specified items diluted eps attributable bms nongaap bristolmyers squibb financial position liquidity capital resources net cash position follows dollars millions cash cash equivalents marketable securities current marketable securities noncurrent total cash cash equivalents marketable securities shortterm borrowings current portion longterm debt longterm debt net cash position cash cash equivalents marketable securities held us approximately billion december remaining billion held primarily lowtax jurisdictions attributable earnings expected indefinitely reinvested offshore cash repatriations subject restrictions certain jurisdictions may subject withholding additional us income taxes believe existing cash cash equivalents marketable securities together cash generated operations issuance commercial paper us sufficient satisfy normal cash requirements least next years including dividends capital expenditures milestone payments working capital maturities longterm debt management continuously evaluates companys capital structure ensure company financed efficiently may result repurchase common stock debt securities termination interest rate swap contracts prior maturity issuance debt securities example issued senior unsecured notes registered public offering generating proceeds billion redeemed repurchased certain notes nearly billion refer item financial statementsnote financial instruments fair value measurements details companys common stock repurchase capacity increased billion october company entered asr agreements repurchase approximately billion common stock february refer item financial statementsnote equity details dividend payments billion billion dividend decisions made quarterly basis board directors capital expenditures approximately billion million million expected approximately billion million higher spending expected result expanding biologics manufacturing capabilities facilityrelated activities example constructing new large scale biologics manufacturing facility ireland produce multiple therapies growing biologics portfolio completed marketable securities portfolio subject changes fair value result interest rate fluctuations market factors may impact results operations investment policy places limits investments amount time maturity investments institution policy also requires investments entered corporate financial institutions meet high credit quality standards refer item financial statementsnote financial instruments fair value measurements details currently two separate billion revolving credit facilities syndicate lenders facilities provide customary terms conditions financial covenants extended october july facility extendable annually one year anniversary date consent lenders borrowings outstanding either revolving credit facility december additional regulations us could passed future may reduce results operations operating cash flow liquidity financial flexibility continue monitor potential impact economic conditions certain european countries related impact prescription trends pricing discounts creditworthiness customers believe economic conditions material impact liquidity cash flow financial flexibility uk voted depart eu june similar companies industry certain regulatory trade labor aspects business likely affected time however currently believe matters related financial effects material impact consolidated results operations financial position liquidity sales uk represent less total revenues annual report credit ratings bms 's longterm shortterm credit ratings assigned moody 's investors service prime respectively negative longterm credit outlook bms 's longterm shortterm credit ratings assigned standard poor 's respectively stable longterm credit outlook bms 's longterm shortterm credit ratings assigned fitch f respectively stable longterm credit outlook longterm ratings reflect agencies ' opinion low default risk somewhat susceptible adverse effects changes circumstances economic conditions shortterm ratings reflect agencies ' opinion good extremely strong capacity timely repayment credit rating downgrade may affect interest rate debt may incur fair market value existing debt ability access capital markets generally cash flows following discussion cash flow activities dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts disbursements activities investing financing activities operating cash flow derived adjusting net earnings noncontrolling interest noncash operating items gains losses attributed investing financing activities changes operating assets liabilities resulting timing differences receipts payments cash transactions recognized results operations result changes cash operating activities reflect timing cash collections customers alliance partners payments suppliers alliance partners employees customer discounts rebates tax payments ordinary course business example annual employee bonuses typically paid first quarter subsequent year addition cash collections continue impacted longer payment terms certain biologic products us primarily newer oncology products including opdivo yervoy empliciti days days longer payment terms used closely align insurance reimbursement timing physicians cancer centers following administration patients billion increase cash provided operating activities primarily attributable higher operating cash flow attributed increased sales timing cash collections payments ordinary course business including winddown abilify alliance lower upfront milestone payments alliance licensing arrangements approximately million partially offset higher income tax payments approximately billion billion decrease cash provided operating activities primarily attributable timing payments alliance partners approximately million particularly active product ingredient supply medicaid rebates abilify higher upfront payments new alliance licensing agreements approximately million timing customer collections resulting primarily higher net product sales including extended payment terms certain new products less factoring approximately million partially offset timing cash collections payments ordinary course business including among items changes inventory levels particularly related abilify bristolmyers squibb investing activities cash requirements investing activities include cash used acquisitions manufacturing facilityrelated capital expenditures purchases marketable securities maturities greater days reduced proceeds business divestitures including royalties sale maturity marketable securities billion decrease cash used investing activities primarily attributable higher net redemptions marketable securities approximately billion reinvested cash equivalents manage credit interest rate risks lower asset acquisition payments approximately million asset acquisitions include cormorant padlock flexus cardioxyl higher business divestiture proceeds approximately million including royalties contingent consideration received subsequent divestiture divestitures include certain otc products investigational hiv businesses mount vernon indiana manufacturing facility ixempra mature otc product businesses partially offset higher capital expenditures approximately million billion decrease cash provided investing activities primarily attributable lower business divestiture proceeds billion divestitures include mount vernon indiana manufacturing facility ixempra mature otc product businesses diabetes business higher asset acquisition payments approximately million asset acquisitions include flexus cardioxyl ipierian higher capital expenditures approximately million partially offset lower net purchases marketable securities billion financing activities cash requirements financing activities include cash used pay dividends repurchase common stock repay longterm debt borrowings reduced proceeds exercise stock options issuance longterm debt borrowings million decrease cash used financing activities primarily attributable lower longterm net debt repayments approximately million higher net shortterm borrowings approximately million consisting primarily changes bank overdrafts partially offset repurchase common stock approximately million none million increase cash used financing activities primarily attributable lower net shortterm borrowings approximately million consisting primarily changes bank overdrafts contractual obligations payments due period contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debta operating leases purchase obligations uncertain tax positionsb longterm liabilitiesc total includes estimated future interest payments periodic cash settlements derivatives b includes shortterm uncertain tax benefits uncertainties regarding timing resolution c include pension liability annual report addition committed aggregated billion potential future research development milestone payments third parties inlicensing asset acquisitions development programs including earlystage milestones billion milestones achieved phase iii clinical trials latestage milestones billion milestones achieved post phase iii clinical trials payments generally due payable upon achievement certain developmental regulatory milestones specific timing predicted agreements also provide salesbased milestones aggregating billion would obligated pay alliance partners upon achievement certain sales levels addition royalties also certain manufacturing development commercialization obligations connection alliance arrangements practicable estimate amount obligations refer item financial statementsnote alliances information regarding alliances discussion contractual obligations refer item financial statementsnote income taxes note financial instruments fair value measurementsand note pension postretirement postemployment liabilities sec consent order fcpa settlement previously disclosed august entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit quarterly report form q period ended september terms consent agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis maintain imas us pharmaceutical wholesalers account nearly gross us revenues current terms imas wholesaler customers provide us weekly information respect months hand productlevel inventories amount outmovement products three largest wholesalers currently account approximately gross us revenues inventory information received wholesalers together internal information used estimate months hand product level inventories wholesalers estimate months hand product inventory levels us businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast nonus business significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly rely variety methods estimate months hand product level inventories business units believe abovedescribed procedures provide reasonable basis ensure compliance consent addition previously disclosed october company reached civil settlement sec alleged fcpa violations company agreed pay approximately million disgorgement penalties interest part settlement company also agreed twoyear selfmonitoring period reporting government maintaining procedures ensure compliance recently issued accounting standards recently issued accounting standards refer item financial statementsnote accounting policiesrecently issued accounting standards bristolmyers squibb critical accounting policies preparation financial statements requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses critical accounting policies significantly impact financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain uncertainty actual results may vary estimates revenue recognition accounting policy revenue recognition substantial impact reported results relies certain estimates revenue recognized persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally upon shipment except certain eu markets occur delivery products customer deferred approximately million invoiced daklinza early access program france portion amount recognized revenue final pricing obtained revenue also reduced grosstonet sales adjustments discussed involve significant estimates judgment considering legal interpretations applicable laws regulations historical experience payer channel mix eg medicare medicaid current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel estimates assessed period adjusted required revised information actual experience alliance arrangements involving delivery one element undelivered element evaluated whether qualifies separate unit accounting consideration fixed determinable allocated undelivered element recognized related goods services delivered limited consideration contingent upon future deliverables consideration associated contingent milestones royalties allocated among underlying elements amounts determined payable bms grosstonet adjustments following categories grosstonet adjustments involve significant estimates judgments information obtained external sources refer total revenues discussion analysis significant category grosstonet sales adjustments chargebacks cash discounts us business participates programs government entities significant us department defense us department veterans affairs parties including covered entities b drug pricing program whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower program price wholesalers charge us difference acquisition cost lower program price accounts receivable reduced estimated amount unprocessed chargeback claims attributable sale typically within two four week time lag us certain countries cash discounts offered incentive prompt payment generally approximating sales price accounts receivable reduced estimated amount unprocessed cash discounts typically within one month time lag medicaid medicare rebates us business participates state government medicaid programs qualifying federal state government programs requiring discounts rebates participating state local government entities discounts rebates provided programs included medicaid rebate accrual medicaid rebates also extended drugs used managed medicaid plans estimated amount unpaid unbilled rebates presented liability rebates discounts offered managed healthcare organizations us managing prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit also pay point service discount centers medicare medicaid services medicare part beneficiaries coverage gap donut hole estimated amount unpaid unbilled rebates discounts presented liability annual report rebates returns discounts adjustments grosstonet sales adjustments include sales returns programs based applicable laws regulations individual nonus countries well rebates offered managed healthcare organizations us lesser extent nonus programs include several different pricing schemes cost caps volume discounts outcomebased pricing schemes pricing clawbacks based sales individual companies aggregation companies participating specific market estimated amount unpaid unbilled rebates discounts presented liability estimated returns established products determined considering historical experience factors including levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products lower demand following loss exclusivity estimated amount product returns presented liability estimated returns new products determined considering historical sales return experience similar products within product line similar therapeutic area andor similar distribution model defer recognition revenue right return expires sufficient historical experience estimate sales returns developed limited circumstances insufficient historical experience products similar therapeutic area distribution method characteristic available typically occurs new product extension existing line product historical experience products similar therapeutic category lacking estimated levels inventory distribution channel projected demand also considered estimating sales returns new products use information external sources information external sources used estimate grosstonet adjustments estimate inventory wholesalers based projected prescription demandbased sales products historical inventory experience well analysis third party information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals also continued practice combining retail mail prescription volume retailequivalent basis use methodology internal demand forecasts also use information external sources identify prescription trends patient demand average selling prices estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date receive thirdparty information retirement benefits accounting pension postretirement benefit plans requires actuarial valuations based significant assumptions discount rates expected longterm rates return plan assets consultation actuaries significant assumptions others salary growth retirement turnover healthcare trends mortality rates evaluated selected based expectations actual experience remeasurement date pension expense could vary within range outcomes material effect reported earnings projected benefit obligations future cash funding actual results given year may differ estimated economic factors yield high quality corporate bonds coincides cash flows plans estimated payouts used determining discount rate citi pension discount curve used us plans present value benefit obligations december us pension plans determined using discount rate assumed discount rate used determining us pension plans projected benefit obligation december reduced additional projected benefit obligation would increase approximately million expected longterm rate return plan assets estimated considering expected returns individual asset classes input external advisors also consider longterm historical returns including actual performance compared benchmarks similar investments us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increase million detailed discussion retirement benefits refer item financial statementsnote pension postretirement postemployment liabilities bristolmyers squibb business combinations divestitures goodwill intangible assets acquired business combinations licensing transactions billion representing total assets december accounting transactions business combinations divestitures significantly different asset acquisitions divestitures example acquired iprd capitalized business combinations expensed asset acquisitions fair value contingent consideration goodwill recognized business combination transactions likewise portion reporting unit constitutes business divested goodwill associated business included carrying value business determining gain loss derecognition goodwill occur asset dispositions result important determine whether business asset group assets acquired divested business defined asc business combinations integrated set inputs processes capable generating outputs ability provide return investors owners typical inputs include longlived assets including intangible assets rights use longlived assets intellectual property ability obtain access required resources typical processes include strategic operational resource management processes typically documented evident organized workforce consider factors determining whether business acquired divested well compound 's development phase commercial products involved example evaluating acquisitions cormorant padlock cardioxyl flexus ipierian concluded significant processes transferred us thus transactions accounted asset acquisitions result amounts allocated lead investigational compounds expensed capitalized addition contingent consideration potential development regulatory approval salesbased milestones sales based royalties included purchase price refer item financial statementsnote acquisitions divestitures discussion acquisitions similarly evaluating divestitures investigational hiv medicines business business comprising alliance reckitt erbitux ixempra businesses comprising alliances medicines company valeant pharmaceuticals international inc diabetes business astrazeneca concluded necessary inputs processes transferred consequently transactions accounted sales businesses resulted allocation goodwill million million million carrying value businesses determining gain sale contingent proceeds related divestitures recognized realized valuation processes also required certain multiple element arrangements include determination judgmental complex matters discussed example bms purchased warrant gives bms exclusive right acquire promedior required determination best estimated selling price two separate elements identified transaction warrant clinical development services similarly divestiture diabetes business astrazeneca required determination best estimated selling price several elements including business supply development agreements including appropriate markups estimated fair value manufacturing facility refer item financial statementsnote alliances discussion transactions impairment intangible assets including iprd intangible assets billion december including licenses million million allocated unapproved products developed technology rights million capitalized software million iprd million intangible assets assessed impairment whenever current facts circumstances warrant review although iprd assessed least annually intangible assets highly vulnerable impairment charges particularly newly acquired assets recently launched products iprd assets initially measured fair value therefore reduction expectations used valuations could potentially lead impairment common potential risks leading impairment include competition earlier expected loss exclusivity pricing pressures adverse regulatory changes clinical trial results delay failure obtain regulatory approval additional development costs inability achieve expected synergies higher operating costs changes tax laws macroeconomic changes complexity estimating fair value intangible assets connection impairment test similar initial valuation considering high risk nature research development industrys success rate bringing developmental compounds market iprd impairment charges likely occur future periods recognized million charge bms phase ii development treatment ipf million including million charge peginterferon lambda phase iii development treatment hcv discussion iprd impairments refer item financial statementsnote goodwill intangible assets annual report property plant equipment property plant equipment tested impairment whenever current facts circumstances require review including whether likely asset disposed prior estimated remaining useful life additionally longlived assets periodically reviewed determine change facts circumstances would result change estimated useful life asset possibly resulting acceleration depreciation circumstances exist estimate undiscounted future cash flows generated asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value expectations future cash flows subject change based upon near longterm production volumes margins generated asset well potential alternative future use accelerated depreciation related charges certain manufacturing rd facilities million million million additional charges continue occur result companys restructuring actions announced fourth quarter contingencies normal course business subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability contractual claims tax matters recognize accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies refer item financial statementsnote accounting policiescontingencies note income taxes note legal proceedings contingencies income taxes valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecasts future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made deferred tax assets billion december net valuation allowances billion billion december net valuation allowances billion deferred tax assets related us federal net operating loss carryforward million us federal tax credit carryforward million recognized december net operating loss carryforward expires varying amounts beginning us federal tax credit carryforward expires varying amounts beginning realization carryforwards dependent generating sufficient domesticsourced taxable income prior expiration million valuation allowance established item december although assured believe likely deferred tax assets valued realized taxes provided undistributed earnings foreign subsidiaries expected reinvested indefinitely offshore prior mead johnson splitoff following transactions occurred internal spinoff mead johnson shares still owned us ii conversion mead johnson class b shares class shares iii conversion mead johnson company limited liability company transactions well splitoff mead johnson exchange offer qualify taxexempt transactions internal revenue code based upon private letter ruling received internal revenue service related conversion mead johnson class b shares class shares outside legal opinions certain assumptions representations covenants mead johnson relied upon regarding future conduct business matters could affect tax treatment exchange example current tax law generally creates presumption exchange would taxable us mead johnson shareholders engage transactions result greater change stock ownership four year period beginning two years exchange offer unless established exchange offer part plan series related transactions effect change ownership internal spinoff exchange offer determined qualify tax exempt transaction transaction could subject tax exchange taxable sale us market value bristolmyers squibb addition negative basis ela existed investment stock mead johnson prior transactions received opinion outside legal counsel effect likely eliminated ela part transactions taxable income respect ela tax law area complex possible even internal spinoff exchange offer tax exempt internal revenue code irs could assert additional taxable income period respect ela could exposed additional taxes occur based upon understanding internal revenue code opinion outside legal counsel tax reserve million established reducing gain disposal mead johnson included discontinued operations agreed certain tax related indemnities mead johnson set forth tax sharing agreement including certain taxes related business prior completion ipo created part restructuring facilitate ipo mead johnson also agreed indemnify us potential tax effects resulting breach certain representations discussed well certain transactions related acquisition mead johnsons stock assets liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known example additional reserves million established certain transfer pricing matters related periods discussions income taxes refer item financial statementsnote accounting policiesincome taxes note income taxes product pipeline developments rd programs managed portfolio basis early discovery latestage development include balance early stage latestage programs support future growth late stage rd programs phase iii development include investigational compounds initial indications additional indications formulations marketed products spending programs represent approximately annual rd expenses last three years individual investigational compound marketed product represented rd expenses last three years except opdivo latestage development programs could potentially impact revenue earnings within next years regulatory approvals obtained products successfully commercialized following developments marketed products late stage pipeline product indication date developments december jmhlw manufacturing marketing approval treatment relapsed refractory chl received alliance partner ono december bms seattle genetics inc announced results phase iii study evaluating adcetris brentuximab combination opdivo relapsed refractory chl november ec approval treatment adult patients relapsed refractory chl asct treatment brentuximab vedotin chl announced new results checkmate phase ii trial evaluating opdivo patients october chl including patients received brentuximab vedotin andor auto hsct announced results checkmate phase ii trial evaluating opdivo patients june chl opdivo fda approval treatment patients chl relapsed progressed may autohsct posttransplantation brentuximab vedotin announced results ono phase iii trial evaluating opdivo patients unresectable advanced recurrent gastric cancer refractory intolerant standard january therapy november announcement stated study met primary endpoint gastric cancer ono alliance partner conducted trial december bms 's alliance partner ono submitted supplemental application opdivo treatment unresectable advanced recurrent gastric cancer announced extended followup data ca phase trial evaluating opdivo april heavily pretreated advanced melanoma patients melanoma fda expanded use opdivo single agent include previously untreated braf january mutation positive advanced melanoma patients annual report product indication date developments fda approval treatment patients previously treated locally advanced muc february type bladder cancer announced results checkmate phase ii trial evaluating opdivo platinum october refractory patients muc muc announced ema validated company 's type ii variation application seeks september extend current indications include treatment locally advanced muc adults failure prior platinumcontaining therapy announced data checkmate phase iii trial evaluating opdivo patients june muc platinumbased therapy announced updated results two phase iii trials checkmate checkmate october evaluating opdivo previously treated metastatic nsclc patients presented final primary analysis checkmate phase iii trial evaluating opdivo firstline monotherapy patients advanced nsclc whose tumors expressed pd october nsclc l top line results disclosed august showed checkmate meet primary endpoint superior pfs announced data two phase iii trials checkmate checkmate evaluating may opdivo versus docetaxel previously treated metastatic nsclc opdivo april ec approval treatment previously treated patients metastatic nsq nsclc jmhlw manufacturing marketing approval treatment unresectable august metastatic rcc received alliance partner ono announced longterm results two doseranging studies phase ca study rcc june phase ii ca study evaluating opdivo patients previously treated advanced rcc april ec approval treatment previously treated patients advanced rcc november fda approval treatment patients scchn disease progression platinumbased therapy announced new data checkmate phase iii trial evaluating opdivo patients october recurrent metastatic scchn platinum therapy compared investigator 's choice therapy scchn ema validated japan bms 's alliance partner ono submitted applications july opdivo patients previously treated recurrent metastatic scchn announced data checkmate phase iii trial evaluating opdivo patients recurrent metastatic scchn platinum therapy compared investigator 's choice april therapy january checkmate stopped early due dmc concluding study met primary endpoint announced data checkmate phase ii trial evaluating opdivo alone colorectal cancer june combination yervoy patients previously treated metastatic colorectal cancer including msih announced results two trials checkmate phase iii checkmate phase ii june evaluating opdivoyervoy combination regimen previously untreated advanced melanoma ec approval treatment unresectable metastatic melanoma regardless braf may melanoma mutational status announced data checkmate phase ii trial evaluating opdivoyervoy april combination regimen previously untreated advanced melanoma fda expanded use treatment previously untreated unresectable metastatic january opdivoyervoy melanoma regardless braf mutational status announced additional results checkmate phase iii trial investigating two november muc combination schedules opdivoyervoy patients locally advanced muc previously treated platinumbased therapy announced updated findings checkmate phase ib trial evaluating opdivo december nsclc monotherapy combination yervoy patients chemotherapynave advanced nsclc data previously announced june announced updated results checkmate phase trial evaluating opdivo rcc october yervoy combination regimen previously treated treatmentnave patients metastatic rcc december announced updated results checkmate phase iii trial evaluating opdivo sclc monotherapy combination yervoy previously treated sclc patients bristolmyers squibb product indication date developments september jmhlw manufacturing marketing approval combination revlimid lenalidomide dexamethasone treatment multiple myeloma empliciti multiple myeloma ec approval treatment multiple myeloma combination therapy revlimid may dexamethasone patients received least one prior therapy announced new data ca phase iii trial evaluating yervoy stage iii yervoy melanoma october melanoma patients high risk recurrence following complete surgical resection september ec approval combination mtx treatment highly active progressive disease adult patients ra previously treated mtx announced commercial launch orencia clickject autoinjector new self july orencia ra administered autoinjector adults moderate severe ra presented findings first us observational study exploring moderate severe ra june patients ' response treatment based baseline status two biomarkers poor prognosis anticcp rf december jmhlw manufacturing marketing approval ximency combination tablet contains daclatasvir asunaprevir beclabuvir treatment hcv genotype fda approval daklinza use sofosbuvir treatment chronic hcv february hepatitis c genotypes three additional patient populations hcv portfolio announced results first completed alloral chronic hcv regimen daklinza february combination asunaprevir phase iii trial includes chinese patient population ec approval daklinza use sofosbuvir treatment chronic hcv three january new patient populations ec approval reyataz oral powder indicated hivinfected children least months reyataz hiv june kg optimized reyataz capsule pediatric dosing recommendations special note regarding forwardlooking statements annual report including documents incorporated reference written oral statements make time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years included important factors cautionary statements included annual report particularly item risk factors believe could cause actual results differ materially forwardlooking statement although believe prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made undertake obligation release publicly revisions forwardlooking statements result new information future events otherwise annual report quantitative qualitative disclosures market risk exposed market risk resulting changes currency exchange rates interest rates certain derivative financial instruments used available costeffective basis hedge underlying economic exposure financial instruments including derivatives subject counterparty credit risk considered part overall fair value measurement derivative financial instruments used trading purposes foreign exchange risk significant amounts revenues earnings cash flow exposed changes foreign currency rates primary net foreign currency translation exposures euro japanese yen chinese renminbi foreign currency forward contracts used manage risk primarily arises certain intercompany purchase transactions designated foreign currency cash flow hedges appropriate addition exposed foreign exchange transaction risk arising nonfunctional currency denominated assets liabilities earnings denominated nonus dollar currencies foreign currency forward contracts used offset exposures designated hedges estimate appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million december reducing earnings remaining life contracts also exposed translation risk nonus dollardenominated net assets nonus dollar borrowings used hedge foreign currency exposures net investment certain foreign affiliates designated hedges net investments effective portion foreign exchange gains losses hedges included foreign currency translation component accumulated comprehensive incomeloss net investment decreases equivalent value nonus debt borrowings change remeasurement basis debt would subject recognition income changes occur additional information refer item financial statementsnote financial instruments fair value measurements interest rate risk use fixedtofloating interest rate swap contracts designated fair value hedges forward starting interest rate swap contracts designated cash flow hedges part interest rate risk management strategy contracts intended provide us appropriate balance fixed floating rate debt forward starting swap contracts used manage interest rate future debt issuances estimate increase basis points shortterm longterm interest rates would decrease fair value interest rate swap contracts million decrease basis points shortterm longterm interest rates would decrease fair value forward starting interest rate swap contracts million thereby reducing earnings remaining life contracts estimate increase basis points longterm interest rates would decrease fair value longterm debt million marketable securities subject changes fair value result interest rate fluctuations market factors policy invest institutions meet high credit quality standards estimate increase basis points interest rates general would decrease fair value debt investment portfolio approximately million credit risk although material certain european governmentbacked entities higher risk default greece portugal italy spain monitored economic factors including credit ratings creditdefault swap rates debttogross domestic product ratios entity specific factors historically exposure limited factoring receivables credit exposures europe may increase future due reductions factoring arrangements ongoing sovereign debt crisis monitor investments counterparties objective minimizing concentrations credit risk investment policy establishes limits amount time maturity investments individual counterparty policy also requires investments entered corporate financial institutions meet high credit quality standards use derivative instruments exposes us credit risk fair value derivative instrument contract positive exposed credit risk counterparty fails perform fair value derivative instrument contract negative counterparty exposed credit risk fail perform obligation collateral required party whether derivatives asset liability position policy diversifying derivatives counterparties mitigate overall risk counterparty defaults additional information refer item financial statementsnote financial instruments fair value measurements bristolmyers squibb consolidated statements earnings dollars shares millions except per share data year ended december earnings net product sales alliance revenues total revenues cost products sold marketing selling administrative research development incomeexpense total expenses earnings income taxes provision income taxes net earnings net earnings attributable noncontrolling interest net earnings attributable bms earnings per common share basic diluted cash dividends declared per common share consolidated statements comprehensive income dollars millions year ended december comprehensive income net earnings comprehensive incomeloss net taxes reclassifications earnings derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation total comprehensive loss comprehensive income comprehensive income attributable noncontrolling interest comprehensive income attributable bms accompanying notes integral part consolidated financial statements annual report consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable securities receivables inventories prepaid expenses total current assets property plant equipment goodwill intangible assets deferred income taxes marketable securities assets total assets liabilities current liabilities shortterm borrowings current portion longterm debt accounts payable accrued liabilities deferred income income taxes payable total current liabilities deferred income income taxes payable pension liabilities longterm debt total liabilities commitments contingencies note equity bristolmyers squibb company shareholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total bristolmyers squibb company shareholders ' equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements bristolmyers squibb consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization net deferred income taxes stockbased compensation impairment charges pension settlements amortization divestiture gains royalties net asset acquisition charges adjustments changes operating assets liabilities receivables inventories accounts payable deferred income income taxes payable net cash provided operating activities cash flows investing activities sale maturities marketable securities purchase marketable securities capital expenditures divestiture proceeds acquisition payments net cash provided byused investing activities cash flows financing activities shortterm borrowings net issuance longterm debt repayment longterm debt interest rate swap contract terminations issuance common stock repurchase common stock dividends net cash used financing activities effect exchange rates cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statements annual report note accounting policies recently issued accounting standards basis consolidation consolidated financial statements prepared conformity us gaap including accounts bristolmyers squibb company controlled majorityowned subsidiaries certain variable interest entities intercompany balances transactions eliminated material subsequent events evaluated disclosed report issuance date refer summary abbreviated terms end annual report terms used throughout document alliance license arrangements assessed determine whether terms provide economic control entity requiring consolidation entity entities controlled means majority voting interest referred variable interest entities consolidated bms power direct activities variable interest entity significantly impacts economic performance obligation absorb losses right receive benefits could potentially significant entity use estimates judgments preparation financial statements requires use management estimates judgments assumptions significant assumptions estimates determining fair value potential impairment intangible assets sales rebate return accruals legal contingencies income taxes estimated selling prices used multiple element arrangements determining acquisition divestiture business asset pension postretirement benefits actual results may differ estimated results reclassifications certain prior period amounts reclassified conform current period presentation reclassifications provide concise financial statement presentation additional information disclosed notes material prior presentation current presentation consolidated included marketing selling administrative advertising product promotion statements earnings expenses assets heldforsale included prepaid expenses accrued expenses consolidated balance accrued rebates returns combined accrued liabilities sheets dividends payable pension postretirement postemployment liabilities combined pension liabilities liabilities net earnings attributable noncontrolling interest included adjustments consolidated statements divestiture gains royalties included adjustments divestiture gains royalties cash flows asset acquisition charges included adjustments asset acquisition charges revenue recognition revenue recognized persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally time shipment including supply commercial products alliance partners principal end customer sale however certain revenue nonus businesses recognized date receipt customer alliance revenue related abilify atripla recognized products sold end customer alliance partner royalties recognized thirdparty sales reliably measurable collectability reasonably assured refer note alliances detail regarding alliances revenue reduced time recognition expected sales returns discounts rebates sales allowances based historical experience updated changes facts circumstances including impact applicable healthcare legislation revenue deferred historical experience products similar therapeutic category similar operational characteristics right return longer exists sufficient historical experience estimate sales returns developed bristolmyers squibb income taxes provision income taxes includes income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax basis assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made tax benefits recognized uncertain tax position likely tax position sustained examination taxing authorities based technical merits position tax benefit recognized financial statements particular tax position based largest benefit likely realized upon settlement cash cash equivalents cash cash equivalents include bank deposits time deposits commercial paper money market funds cash equivalents consist highly liquid investments original maturities three months less time purchase recognized cost approximates fair value marketable securities investments companies marketable securities classified availableforsale date purchase reported fair value fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity investments less owned companies accounted using equity method accounting ability exercise significant influence maintained share net income losses equity investments included incomeexpense equity investments reviewed impairment assessing decline market value investment carrying value temporary considers intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value less cost investee 's financial condition inventory valuation inventories stated lower average cost market property plant equipment depreciation expenditures additions renewals improvements capitalized cost depreciation computed straightline method based estimated useful lives related assets ranging years buildings years machinery equipment fixtures impairment longlived assets current facts circumstances periodically evaluated determine carrying value depreciable assets held used may recoverable circumstances exist estimate undiscounted future cash flows generated longlived asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques using unobservable fair value inputs discounted value estimated future cash flows capitalized software eligible costs obtain internal use software capitalized amortized estimated useful life software annual report acquisitions businesses acquired consolidated upon obtaining control fair value assets acquired liabilities assumed recognized date acquisition excess purchase price estimated fair values net assets acquired recognized goodwill business acquisition costs expensed incurred contingent consideration potential development regulatory approval salesbased milestones salesbased royalties included purchase price business combinations excluded asset acquisitions amounts allocated lead investigational compounds asset acquisitions expensed date acquisition goodwill acquired inprocess research development intangible assets fair value intangible assets typically determined using income method utilizing level fair value inputs market participant valuations assume global view considering potential jurisdictions indications based discounted aftertax cash flow projections risk adjusted estimated probability technical regulatory success iprd finitelived intangible assets including licenses developed technology rights iprd projects reach commercialization amortized straightline basis estimated useful life estimated useful lives determined considering period assets expected contribute future cash flows goodwill tested least annually impairment assessing qualitative factors performing quantitative analysis determining whether likely fair value net assets carrying amounts examples qualitative factors assessed include share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year relevant factor assessed individually aggregate iprd tested impairment annual basis frequently events occur circumstances change would indicate potential reduction fair values assets carrying value carrying value iprd determined exceed fair value impairment loss recognized difference finitelived intangible assets tested impairment facts circumstances suggest carrying value asset may recoverable carrying value exceeds projected undiscounted pretax cash flows intangible asset impairment loss equal excess carrying value estimated fair value discounted aftertax cash flows recognized restructuring restructuring charges recognized result actions streamline operations rationalize manufacturing facilities estimating impact restructuring plans including future termination benefits exit costs requires judgment actual results could vary estimates contingencies loss contingencies legal proceedings claims may occur wide range matters including government investigations shareholder lawsuits product environmental liability contractual claims tax matters accruals recognized probable liability incurred amount loss reasonably estimated gain contingencies including contingent proceeds related divestitures recognized realized legal fees expensed incurred shipping handling costs shipping handling costs included marketing selling administrative expenses million million million advertising product promotion costs advertising product promotion costs included marketing selling administrative expenses million million million advertising product promotion costs expensed incurred foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized oci bristolmyers squibb research development research development costs expensed incurred clinical study costs accrued service periods specified contracts adjusted necessary based upon ongoing review level effort costs actually incurred strategic alliances third parties provide licensing rights develop manufacture market andor sell pharmaceutical products rights owned party research development recognized net reimbursements connection alliance agreements upfront contingent milestone payments asset acquisitions investigational compounds also included research development expenses cash flow upfront contingent milestone payments licensing investigational compounds included operating activities asset business acquisitions included investing activities divestiture proceeds included investing activities well royalties consideration received subsequent related sale asset business adjustments reflected operating activities include divestiture gains losses related royalties research development asset acquisition charges gains losses debt redemption changes fair value written option liabilities recently issued accounting standards may fasb issued new accounting standard related revenue recognition requires entity recognize amount revenue expects entitled transfer promised goods services customers new standard subsequent amendments issued replace existing revenue recognition standards us gaap becomes effective january five step model utilized achieve core principle identify customer contract identify contracts performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied new standard applied retrospectively prior reporting period presented retrospectively cumulative effect change recognized date initial application retained earnings disclosures regarding nature amount timing uncertainty revenue cash flows customer contracts also required companys assessment new standards impact substantially complete based current contracts currently believe timing recognizing revenue typical net product sale customers significantly change however new standard longer require transaction price fixed determinable certain variable consideration might recognized prior occurrence resolution contingent event subject revenue reversal constraint result certain revenue previously deferred current standard transaction price fixed determinable eg early access programs accounted variable consideration might recognized earlier provided terms sufficient reliably estimate ultimate price expected realized addition future royalties related certain alliance arrangements eg sanofi japan erbitux arrangements disclosed note alliances estimated recognized prior third party sale occurring provided probable estimated amounts would reversed future however timing royalties salesbased milestones forms contingent consideration resulting divestiture businesses eg diabetes north american erbitux businesses disclosed note alliances well royalties salesbased royalties licensing arrangements expected change new standards guidance pertaining separation licensing rights related fee recognition expected significantly change timing recognizing revenue existing alliance arrangements currently generating revenue company currently anticipates adopt new standard modified retrospective basis cumulative effect change reflected retained earnings january restate prior periods result certain future royalties discussed estimated presented cumulative effect accounting change excluded results operations beginning subsequent significant revisions estimated amounts variable consideration pertaining similar arrangements entered subsequent adoption new standard also need estimated accounted comparable manner initial estimate reflected revenue assessed subsequent reporting period significant changes business processes systems controls currently expected required january fasb issued amended guidance recognition measurement presentation disclosures financial instruments effective january early adoption permitted new guidance requires fair value adjustments equity securities readily determinable fair values currently classified availableforsale reported earnings new guidance also requires qualitative impairment assessment equity investments without readily determinable fair value charge earnings impairment exists company expect amended standard material impact companys results operations annual report february fasb issued amended guidance lease accounting amended guidance requires recognition right ofuse asset lease liability initially measured present value future lease payments leases term longer months guidance effective beginning early adoption permitted modified retrospective approach although companys assessment amended standard completed minimal impacts results operations expected undiscounted value lease obligations approximately million december consisting primarily facility leases accounted operating leases initial rightofuse asset lease liability amount reflected upon adoption subject several factors including actual lease portfolio earliest date initial application selection appropriate discount rate determining individual fixed lease payments terms including renewal periods reasonably certain occur march fasb issued amended guidance sharebased payment transactions excess tax benefits deficiencies recognized consolidated statement earnings rather capital excess par value stock prospective basis policy election available account forfeitures occur cumulative effect change recognized adjustment retained earnings date adoption excess tax benefits within consolidated statement cash flows presented operating activity prospective retrospective application cash payments tax authorities connection shares withheld statutory tax withholding requirements presented financing activity retrospective application guidance effective beginning expected reduction income tax expense excess tax benefits expected material company continue current practice relating accounting forfeitures cash flow presentation changes discussed increase net cash provided operating activities net cash used financing activities million million june fasb issued amended guidance measurement credit losses financial instruments entities required use forwardlooking estimated loss model availableforsale debt security credit losses recognized allowances rather reduction amortized cost guidance effective beginning early adoption permitted modified retrospective approach company expect amended standard material impact companys results operations october fasb issued amended guidance income tax accounting intraentity transfers assets inventory amended guidance requires tax consequences transfers assets members consolidated group recognized period transfer takes place excluding inventory guidance effective beginning early adoption permitted first quarter modified retrospective approach company early adopt amended standard beginning first quarter result prepaid receivables deferred tax assets attributed internal intellectual property transfers approximately billion reduced cumulative effect accounting change retained earnings longer amortized component income taxes million per year addition tax impact future internal transfers intellectual property included income tax expense transferred amortized subsequent periods january fasb issued amended guidance revises definition business amendments provide initial screen substantially fair value gross assets acquired disposed concentrated single identifiable asset group similar identifiable assets assets would represent business considered business must input substantive process together significantly contribute ability create outputs business without outputs need organized workforce amendments also narrow definition term outputs guidance effective beginning early adoption permitted prospectively company assessing potential impact amended standard january fasb issued amended guidance simplifies recognition measurement goodwill impairment loss eliminating step quantitative impairment test result impairment charges required amount reporting units carrying amount exceeds fair value amount allocated goodwill guidance effective prospective basis early adoption permitted interim annual goodwill impairment tests performed january company expect amended standard material impact companys results operations bristolmyers squibb note business segment information bms operates single segment engaged discovery development licensing manufacturing marketing distribution sale innovative medicines help patients prevail serious diseases global research development organization supply chain organization responsible discovery development manufacturing supply products regional commercial organizations market distribute sell products business also supported global corporate staff functions segment information consistent financial information regularly reviewed chief executive officer purposes evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross revenues three largest pharmaceutical wholesalers us percentage global gross revenues follows mckesson corporation amerisourcebergen corporation cardinal health inc selected geographic area information follows revenues property plant equipment dollars millions united states europe rest worlda otherb total includes japan represented total revenues respectively b revenues include royalties alliancerelated revenues products sold regional commercial organizations product revenues follows year ended december dollars millions oncology empliciti elotuzumab erbitux cetuximab opdivo nivolumab sprycel dasatinib yervoy ipilimumab cardiovascular eliquis apixaban immunoscience orencia abatacept virology baraclude entecavir hepatitis c franchise reyataz atazanavir sulfate franchise sustiva efavirenz franchise neuroscience abilify aripiprazole mature products total revenues annual report composition total revenues follows year ended december dollars millions net product sales alliance revenues revenues total revenues note alliances bms enters collaboration arrangements third parties development commercialization certain products although arrangements unique nature parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities bms may either inlicense intellectual property owned party outlicense intellectual property party arrangements also typically include research development manufacturing andor commercial activities cover single investigational compound commercial product multiple compounds andor products various life cycle stages rights obligations parties global limited geographic regions refer collaborations alliances partners alliance partners several products empliciti erbitux opdivo sprycel yervoy eliquis orencia sustiva atripla abilify well products comprising diabetes alliance discussed certain mature brands included alliance arrangements payments alliance partners accounted presented results operations considering specific nature payment underlying activities payments relate multiple alliance activities including transfer rights separated individual units accounting standalone value activities occur life arrangements situations arrangement consideration allocated activities rights relative selling price basis multiple alliance activities rights standalone value combined single unit accounting common activities bms alliance partners presented results operations follows bms principal end customer sale product sales included net product sales bms 's alliance partner principal end customer sale bms 's contractual share thirdparty sales andor royalty income included alliance revenue sale commercial products considered part bms 's ongoing major central operations refer revenue recognition included note accounting policies information regarding recognition criteria amounts payable bms alliance partners principal end customer sale supply commercial products included alliance revenue sale commercial products considered part bms 's ongoing major central operations profit sharing royalties salesbased fees payable bms alliance partners included cost products sold incurred cost reimbursements parties recognized incurred included cost products sold marketing selling administrative expenses research development expenses based underlying nature related activities subject reimbursement upfront contingent development approval milestones payable bms alliance partners investigational compounds commercial products deferred amortized shorter contractual term periods related compounds products expected contribute future cash flows amortization presented consistent nature payment arrangement example amounts received investigational compounds presented incomeexpense activities performed time related sale commercial products part bmss ongoing major central operations amounts received commercial products presented alliance revenue sale commercial products considered part bmss ongoing major central operations except astrazeneca alliance pertaining amylin products see discussion specific astrazeneca alliance disclosure herein upfront contingent approval milestones payable bms alliance partners commercial products capitalized amortized shorter contractual term periods related products expected contribute future cash flows amortization included cost products sold upfront contingent milestones payable bms alliance partners prior regulatory approval expensed incurred included research development expenses royalties contingent consideration payable bms alliance partners related divestiture businesses included income earned bristolmyers squibb equity net income affiliates included incomeexpense payments bms alliance partners presented cash flows operating activities except otherwise described selected financial information pertaining alliances follows including net product sales bms principal thirdparty customer sale products subject alliance expenses summarized include amounts attributed activities products alliance payments alliance partners related amortization payments deferred capitalized year ended december dollars millions revenues alliances net product sales alliance revenues total revenues payments tofrom alliance partners cost products sold marketing selling administrative research development incomeexpense noncontrolling interest pretax selected alliance balance sheet information december dollars millions receivables alliance partners accounts payable alliance partners deferred income alliancesa includes unamortized upfront milestone licensing proceeds revenue deferrals attributed atripla undelivered elements diabetes business divestiture proceeds amortization deferred income primarily related alliances million million million upfront payments new licensing alliance agreements including options license acquire related assets charged research development expenses million million million specific information pertaining significant alliances discussed including nature purpose significant rights obligations parties specific accounting policy elections income statement classification amounts attributable payments parties pfizer bms pfizer parties worldwide codevelopment cocommercialization agreement eliquis anticoagulant discovered bms pfizer funds development costs depending study profits losses shared equally global basis except certain countries pfizer commercializes eliquis pays bms compensation based percentage net sales upon entering agreement coexclusive license rights product granted pfizer exchange upfront payment potential milestone payments parties assumed certain obligations actively participate alliance actively participate joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms manufactures product alliance principal end customer product sales us significant countries europe well canada australia china japan south korea bms transferred full commercialization rights pfizer certain smaller countries order simplify operations transferred countries bms supplies product pfizer cost plus percentage net sales end customers company determined rights transferred pfizer standalone value rights sold separately bms party could pfizer receive benefit delivered rights without fulfillment ongoing obligations bms alliance agreement including exclusive supply arrangement global alliance treated single unit accounting upfront proceeds subsequent contingent milestone proceeds amortized life related product annual report bms received million nonrefundable upfront milestone licensing payments related eliquis december amortization eliquis deferred income included income eliquis commercial product commencement alliance summarized financial information related alliance follows year ended december dollars millions revenues pfizer alliance net product sales alliance revenues total revenues payments tofrom pfizer cost products sold profit sharing incomeexpense amortization deferred income selected alliance cash flow information deferred income selected alliance balance sheet information december dollars millions deferred income gilead bms gilead joint ventures us us canada europe develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg combining sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead joint ventures consolidated gilead parties actively participate joint executive committee various operating committees direct oversight activities joint ventures joint ventures purchase sustiva truvada api bulk form parties complete finishing atripla joint ventures gilead sell distribute atripla principal end customer product sales parties longer coordinate joint promotional activities alliance revenue recognized atripla include bulk efavirenz component atripla based relative ratio average respective net selling prices truvada sustiva alliance revenue deferred related alliance receivable recognized combined product sold thirdparty customers europe following loss exclusivity sustiva effective january percentage atripla net sales europe recognized bms equal difference average net selling prices atripla truvada alliance continue europe either party terminates arrangement last patent expires allows market exclusivity atripla us agreement may terminated gilead upon launch generic version sustiva bms upon launch generic version truvada individual components loss exclusivity us sustiva expected december event gilead terminates agreement upon loss exclusivity sustiva bms receive quarterly royalty payment months following termination payment first months following termination equal atripla net sales multiplied ratio difference average net selling prices atripla truvada atripla average net selling price second third years following termination payment bms reduced respectively atripla net sales multiplied price ratio described bms continue supply sustiva cost plus markup joint ventures threeyear period unless either party elects terminate supply arrangement bristolmyers squibb summarized financial information related alliance follows year ended december dollars millions revenues gilead alliances alliance revenues equity net loss affiliates selected alliance balance sheet information december dollars millions deferred income otsuka bms worldwide commercialization agreement otsuka codevelop copromote abilify excluding certain asian countries us portion agreement expired april agreement expired eu countries june nonus country exclusive right sell abilify agreement expires later april loss exclusivity country parties actively participated joint executive governance operating committees otsuka responsible providing sales force efforts us effective january however bms responsible certain operating expenses various annual limits bms purchased api otsuka completed manufacturing product subsequent sale thirdparty customers us certain countries otsuka assumed responsibility providing funding sales force efforts eu effective april bms also provided certain services including distribution customer management pharmacovigilance bms principal end customer product sales exclusive distributor exclusive right sell abilify otsuka principal end customer product sales us eu alliance revenue includes bmss share total net sales thirdparty customers territories assessment bms 's expected annual contractual share completed quarterly reporting period adjusted based upon reported us abilify net sales year end bms 's annual contractual share alliance revenue recognized interim period quarter exceed amounts due contract bmss contractual share thirdparty net sales eu countries us alliance revenue recognized abilify shipped risks rewards ownership transferred thirdparty customers bms otsuka also alliance sprycel us japan eu oncology territory parties copromote product us eu february copromotion agreement otsuka terminated japan parties actively participate various governance committees however bms control decision making bms responsible development manufacture product also principal end customer product sales ixempra ixabepilone included alliance prior bms 's divestiture business fee paid otsuka based following percentages combined annual net sales sprycel ixempra oncology territory including post divestiture ixempra sales net sales million million million million million million billion excess billion annual periods otsuka contributes first million certain commercial operational expenses relating oncology products oncology territory costs excess million annual report summarized financial information related alliance follows year ended december dollars millions revenues otsuka alliances net product sales alliance revenuesa total revenues payments tofrom otsuka cost products sold oncology fee royalties cost product supply includes amortization extension payment reduction alliance revenue million million lilly bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux us canada japan parties actively participated joint executive committee various operating committees shared responsibilities research development using resources infrastructures lilly manufactured bulk requirements erbitux facilities filling finishing performed third party bms oversight responsibility bms exclusive distribution rights north america responsible promotional efforts north america although lilly right copromote us expense bms principal end customer product sales north america paid lilly distribution fee erbitux net sales north america plus share certain royalties paid lilly bmss rights obligations respect commercialization erbitux north america would expired september october bms transferred rights erbitux north america lilly exchange salesbased royalties described transferred rights include limited full commercialization manufacturing responsibilities transaction accounted business divestiture resulted noncash charge million intangible assets directly related business allocation goodwill bms receive royalties september included income earned royalty rates applicable north america erbitux net sales million million million million plus net sales excess amounts respective years royalties earned million million bms shared rights erbitux japan agreement lilly merck kgaa received pretax profit merck kgaas net sales erbitux japan shared equally lilly bms transferred cocommercialization rights japan merck kgaa exchange salesbased royalties included income earned royalties earned million million bristolmyers squibb summarized financial information related alliance follows year ended december dollars millions revenues lilly alliance net product sales alliance revenues total revenues payments tofrom lilly cost products sold distribution fees royalties amortization intangible asset cost product supply incomeexpense royalties divestiture loss astrazeneca prior diabetes business divestiture discussed bms alliance astrazeneca consisting three worldwide co development commercialization agreements covering onglyza related combination products sold various names farxiga related combination products beginning august bms 's acquisition amylin amylin 's portfolio products including bydureon byetta symlin myalept well certain assets owned amylin including manufacturing facility located west chester ohio coexclusive license rights product products underlying agreement granted astrazeneca exchange upfront payment potential milestone payments parties assumed certain obligations actively participate alliance parties actively participated joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms manufactured products three alliances principal end customer product sales substantially countries alliance agreement rights transferred astrazeneca standalone value rights sold separately bms party could astrazeneca received benefit delivered rights without fulfillment ongoing obligations bms alliance agreements including exclusive supply arrangement global alliance treated single unit accounting result upfront proceeds subsequent contingent milestone proceeds amortized life related products bms received billion nonrefundable upfront payment astrazeneca consideration entering amylin alliance astrazeneca exercised option equal governance rights certain key strategic financial decisions regarding amylin alliance paid bms million consideration payments accounted deferred income amortized based relative fair value predominant elements included alliance estimated useful lives intangible assets related bydureon estimated useful life years byetta estimated useful life years symlin estimated life years myalept estimated useful life years amylin manufacturing plant estimated useful life years amortization presented reduction cost products sold alliance assets acquired shortly commencement alliance astrazeneca entitled share proceeds sale assets amortization acquired amylin intangible assets manufacturing plant also presented cost products sold bms entitled reimbursements capital expenditures related acquired amylin manufacturing facility bms astrazeneca also shared certain tax attributes related amylin alliance prior termination alliance bms received nonrefundable upfront milestone licensing payments million related onglyza million related farxiga amortization onglyza farxiga deferred income included income onglyza farxiga commercial products commencement alliance parties also shared commercialization development expenses equally well profits losses annual report february bms astrazeneca terminated alliance agreements bms sold astrazeneca substantially diabetes business comprising alliance divestiture included shares amylin resulting transfer ohio manufacturing facility intellectual property related onglyza farxiga including bms 's interest outlicensing agreement onglyza japan purchase bmss manufacturing facility located mount vernon indiana substantially employees dedicated diabetes business transferred astrazeneca bms astrazeneca entered several agreements connection sale including supply agreement development agreement transitional services agreement agreements bms obligated supply certain products including active product ingredients onglyza farxiga perform ongoing development activities certain clinical trial programs substantially provide transitional services accounting financial services customer service distribution regulatory development information technology certain administrative services various periods order facilitate orderly transfer business operations consideration transaction includes billion payment closing contingent regulatory salesbased milestone payments billion including million related approval milestones million related salesbased milestones payable royalty payments based net sales payments million certain assets transferred astrazeneca astrazeneca also pay bms required product supply price approximating product cost well negotiated transitional service fees royalty rates net sales follows onglyza farxiga worldwide net sales million onglyza farxiga worldwide net sales million amylin products us net sales stock asset purchase agreement contained multiple elements delivered subsequent closing transaction including china diabetes business transferred mount vernon indiana manufacturing facility transferred activities development supply agreements elements determined standalone value result portion consideration received closing allocated undelivered elements using relative selling price method determining best estimated selling price element remaining amount consideration included calculation gain sale diabetes business contingent milestone royalty payments similarly allocated among underlying elements amounts determined payable bms amounts allocated sale business immediately recognized results operations amounts allocated elements recognized results operations extent element delivered consideration billion accounted including royalties million contingent regulatory milestone payments related approval farxiga us japan approximately billion consideration allocated sale business remaining million allocated undelivered elements described consideration includes million earned royalties including million allocated elements delivered gain sale diabetes business million including million third quarter resulting primarily transfer china diabetes business astrazeneca gain based difference consideration allocated sale business excluding royalties net transaction fees carrying value diabetes business net assets including million allocation goodwill reversal million net deferred tax liabilities attributed amylin consideration million received transfer mount vernon indiana manufacturing facility related inventories resulting gain million amounts allocated delivered elements consideration allocated development supply agreements amortized applicable service periods amortization deferred income attributed development agreement included income sale services considered part bmss ongoing major central operations revenues attributed supply agreement included alliance revenues consideration transaction presented cash flow purposes based allocation process described either investing activity attributed sale business related assets operating activity attributed transitional services supply arrangement development agreement september bms transferred percentage future royalty rights amylin net product sales us cppib transferred rights represent approximately potential future royalties bms entitled exchange transfer bms receive additional tieredbased royalty amylin net product sales us cppib royalties presented income million bristolmyers squibb summarized financial information related astrazeneca alliances follows year ended december dollars millions revenues astrazeneca alliances net product sales alliance revenues total revenues payments tofrom astrazeneca cost products sold profit sharing cost reimbursements astrazeneca incomeexpense amortization deferred income royalties transitional services divestiture gain selected alliance cash flow information deferred income divestiture proceeds selected alliance balance sheet information december dollars millions deferred income services yet performed astrazeneca sanofi bms sanofi codevelopment cocommercialization agreements plavix avaproavalide effective january sanofi assumed essentially worldwide operations alliance exception plavix us puerto rico bms operating partner controlling interest exchange rights transferred sanofi bms receives quarterly royalties january december terminal payment sanofi million end royalties received sanofi territory covering americas australia optout markets former development royalties presented alliance revenues million million million royalties attributed territory covering europe asia continue earned territory partnership included equity net income affiliates alliance revenues attributed supply irbesartan api sanofi million million supply arrangement irbesartan expired annual report summarized financial information related alliance follows year ended december dollars millions revenues sanofi alliances net product sales alliance revenues total revenues payments tofrom sanofi equity net income affiliates noncontrolling interest pretax selected alliance cash flow information distributions tofrom sanofi noncontrolling interest distributions sanofi investment affiliates selected alliance balance sheet information december dollars millions investment affiliates territory covering europe asiaa noncontrolling interest included alliance receivables following summarized financial information interests partnerships sanofi territory covering europe asia consolidated accounted using equity method year ended december dollars millions net sales gross profit net income cost products sold territory covering europe asia includes discovery royalties million million million paid directly sanofi expenses shared based applicable ownership percentages current assets current liabilities include approximately million million million related receivablespayables attributed cash distributions bms sanofi well intercompany balances partnerships within territory ono bms principal end customer product sales exclusive right develop manufacture commercialize opdivo antipd human monoclonal antibody investigated anticancer treatment territories worldwide except japan south korea taiwan ono entitled receive royalties following regulatory approvals territories excluding three countries listed royalty rates net sales north america applicable territories subject customary adjustments alliance arrangement also includes collaboration activities japan south korea taiwan pertaining opdivo yervoy several bms investigational compounds parties right obligation jointly develop commercialize compounds bms responsible supply products profits losses development costs shared equally combination therapies involving compounds parties otherwise sharing activities involving one partys compounds bms ono also alliance codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulations jointly promoted parties assigned customer accounts bms responsible product supply copromotion fee paid party sale made partys assigned customer recorded cost products sold bristolmyers squibb summarized financial information related alliance follows year ended december dollars millions revenues ono alliances net product sales alliance revenues total revenues abbvie bms abbvie alliance empliciti humanized monoclonal antibody treatment multiple myeloma terms alliance bms granted exclusive global rights codevelop commercialize empliciti pdl biopharma inc part abbvie abbvie currently participates joint development us commercialization committees bms final decision making authority parties codeveloping product abbvie funds global development costs bms solely responsible supply distribution sales marketing activities within alliance principal end customer product sales abbvie shares profits losses us paid tiered royalties net sales empliciti outside us bms paid abbvie million certain regulatory milestone events including million approval milestones december abbvie also entitled receive additional milestone payments bms certain regulatory events occur million sales thresholds achieved million agreement may terminated bms either party material breach party subsequent notice period summarized financial information related alliance follows year ended december dollars millions revenues abbvie alliance net product sales fstar october bms entered agreement fstar agreement provides bms exclusive option purchase fstar phase ready lead asset fs targeted therapy development treatment breast gastric cancer among well defined population herpositive patients bms paid million fstar shareholders consideration option grant certain licensing rights included research development expenses responsible conducting funding development fs option exercisable bms 's discretion expires upon earlier days following obtaining proof concept june additional million payable upon exercise option plus additional aggregate consideration million contingent development regulatory approval milestone payments us europe bms obligated provide additional financial support fstar fstar determined business defined asc business combinations result contingent consideration included purchase price goodwill recognized however fstar variable interest entity equity holders lack characteristics controlling financial interest bms determined primary beneficiary power direct activities significantly directly impacting economic performance entity option rights described upon consolidation noncontrolling interest credited million reflect fair value fs iprd asset million deferred tax liabilities annual report promedior september bms purchased warrant gives bms exclusive right acquire promedior biotechnology company whose lead asset prm developed treatment ipf mf warrant exercisable upon completion either ipf mf phase ii clinical studies conducted promedior expected occur earlier upfront payment allocated warrant million included rd expenses remaining million million upfront payment allocated promediors obligation complete phase ii studies amortized expected period phase ii studies allocation determined using level inputs following bms 's review phase ii clinical study results bms elects exercise warrant obligated pay additional million based ipf study results million based mf study results plus additional aggregate consideration million contingent development regulatory approval milestone payments us europe five prime november bms five prime entered exclusive worldwide licensing collaboration agreement development commercialization five primes csfr antibody program including cabiralizumab fpa currently phase iii development immunology oncology indications bms responsible development manufacturing commercialization cabiralizumab subject five primes option conduct certain studies cost develop cabiralizumab pvns combination internal oncology pipeline assets five prime also retained option copromote us agreement replaces previous clinical collaboration agreement two parties consideration licensing rights bms made upfront payment million included rd expense bms also committed pay billion upon achievement contingent development regulatory milestones well future royalties product approved commercialized reckitt may bms reckitt started threeyear alliance several otc products sold primarily mexico brazil reckitt received right sell distribute market products may bms received royalties net sales products exclusively supplied certain products reckitt pursuant supply agreement cost plus markup certain limited assets including marketing authorizations certain employees directly attributed business transferred reckitt start alliance period bms retained ownership assets related business including trademarks covering products framework alliance bms also granted reckitt option acquire trademarks inventory certain assets exclusively related products end alliance period price determined primarily based upon multiple sales may may april alliance modified provide option reckitt purchase bms manufacturing facility located mexico primarily dedicated products included alliance well related employees july reckitt notified bms exercising option may bms sold business million refer note acquisitions divestitures information nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred reckitt fair value option purchase remaining assets using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option determined using level inputs included liabilities bms recognized income million decrease fair value option zero due strengthening us dollar local currencies amount allocated rights transferred reckitt amortized alliance revenue contractual term bristolmyers squibb summarized financial information related alliance follows year ended december dollars millions revenues reckitt alliance alliance revenues incomeexpense divestiture gain selected alliance cash flow information changes operating assets liabilities divestiture proceeds selected alliance balance sheet information december dollars millions deferred income medicines company february bms medicines company entered twoyear alliance recothrom recombinant thrombin use topical hemostat control nonarterial bleeding surgical procedures previously acquired bms connection acquisition zymogenetics inc medicines company received right sell distribute market recothrom global basis two years bms exclusively supplied recothrom medicines company cost plus markup received royalties net sales recothrom certain employees directly attributed business certain assets transferred medicines company start alliance period including biologics license application related regulatory assets bms retained assets related recothrom including patents trademarks inventory bms also granted medicines company option acquire patents trademarks inventory certain assets exclusively related recothrom price determined based multiple sales plus cost remaining inventory held bms time medicines company exercised option acquired business million february nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred medicines company fair value option purchase remaining assets using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option million december determined using level inputs included accrued expenses amount allocated rights transferred medicines company amortized alliance revenue contractual term summarized financial information related alliance follows year ended december dollars millions revenues medicines company alliance alliance revenues incomeexpense divestiture gain selected alliance cash flow information divestiture proceeds annual report valeant october bms pharmaswiss sa whollyowned subsidiary valeant entered alliance certain mature brand products europe valeant received right sell distribute market products europe december bms exclusively supplied products valeant cost plus markup bms also granted valeant option acquire trademarks intellectual property exclusively related products price determined based multiple sales valeant exercised option acquired business million january nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred valeant fair value option purchase remaining assets using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option determined using level inputs included accrued expenses million charge included expenses increase fair value option million amount allocated rights transferred valeant amortized alliance revenue contractual term summarized financial information related alliance follows year ended december dollars millions revenues valeant alliance alliance revenues incomeexpense divestiture gain selected alliance cash flow information changes operating assets liabilities divestiture proceeds note acquisitions divestitures acquisitions acquisitions evaluated determine whether business asset group assets following transactions accounted asset acquisitions since determined business term defined asc business combinations primarily significant processes acquired result amounts allocated lead investigational compounds expensed capitalized consideration transaction allocated follows deferred tax contingent dollars millions year upfront payment rd expense assetsa consideration cormorant padlock cardioxyl flexusb ipierian relates net operating loss tax credit carryforwards b includes million acquisition costs cormorant july bms acquired outstanding shares cormorant private pharmaceutical company focused development therapies cancer rare diseases acquisition provides bms full rights cormorant 's lead candidate humaxil phase iii monoclonal antibody represents potentially complementary immunooncology mechanism action tcell directed antibodies costimulatory molecules contingent consideration includes development regulatory milestone payments bristolmyers squibb padlock april bms acquired outstanding shares padlock private biotechnology company dedicated creating new medicines treat destructive autoimmune diseases acquisition provides bms full rights padlocks pad inhibitor discovery program focused development potentially transformational treatment approaches patients rheumatoid arthritis padlocks pad discovery program may additional utility treating systemic lupus erythematosus autoimmune diseases contingent consideration includes development regulatory milestone payments cardioxyl december bms acquired outstanding shares cardioxyl private biotechnology company focused discovery development novel therapeutic agents cardiovascular disease acquisition provided bms full rights cxl nitroxyl prodrug phase ii development acute decompensated heart failure contingent consideration includes development regulatory salesbased milestone payments flexus april bms acquired outstanding shares flexus private biotechnology company focused discovery development novel anticancer therapeutics acquisition provided bms full rights f preclinical small molecule idoinhibitor targeted immunotherapy addition bms acquired flexus 's idotdo discovery program includes ido selective idotdo dual tdoselective compounds contingent consideration includes development regulatory milestone payments million milestone achieved paid former shareowners flexus commencement phase clinical trial included rd expense ipierian april bms acquired outstanding shares ipierian private biotechnology company focused new treatments tauopathies class neurodegenerative diseases acquisition provided bms full rights ipn preclinical monoclonal antibody treat progressive supranuclear palsy tauopathies contingent consideration includes development regulatory milestone payments future royalties net sales acquired preclinical assets approved commercialized divestitures proceedsa divestiture gains losses royalties dollars millions investigational hiv medicines otc products reckitt diabetes erbitux recothrom mature brand products valeant ixempra includes royalties received subsequent related sale asset business viiv healthcare february bms sold investigational hiv medicines business viiv healthcare includes number programs different stages discovery preclinical clinical development transaction excluded bms 's hiv marketed medicines bms earned transitional fees million certain rd services february bms received upfront payment million bms also receive viiv healthcare contingent development regulatory milestone payments billion salesbased milestone payments billion future tiered royalties products approved commercialized divestitures refer note alliances discussion divestiture transactions reckitt lilly medicines company valeant astrazeneca revenues pretax earnings related businesses material excluding divestiture gains annual report assets heldforsale assets heldforsale million december included prepaid expenses amount consisted primarily goodwill related investigational hiv medicines business business comprising alliance reckitt allocation goodwill determined using relative fair value applicable business company 's reporting unit revenues pretax earnings related businesses material excluding divestiture gains note incomeexpense incomeexpense includes year ended december dollars millions interest expense investment income provision restructuring litigation settlements equity net income affiliates divestiture gains royalties licensing income transition service fees pension charges intangible asset impairment equity investment impairment written option adjustment loss debt redemption incomeexpense litigation settlements includes million contractual dispute related license transition service fees related divestiture diabetes investigational hiv businesses diabetes business written option adjustments included change fair value written option liability attributed reckitt alliance valeant reckitt debt redemption loss million resulted early redemption euro notes tender offer certain debt securities includes unrealized foreign exchange loss million resulting remeasurement bolivar denominated cash monetary balances bmss whollyowned subsidiary venezuela december exchange rate changed simadi rate official cencoex rate considering limited amount foreign currency exchanged second half published exchange rates continuing deterioration economic conditions venezuela note restructuring october company announced restructuring evolve streamline operating model expects incur charges connection employee workforce reductions early site exits charges expected incurred range billion billion consist employee termination benefit costs contract termination costs accelerated depreciation property plant equipment impairments longlived assets site shutdown costs cash outlays connection actions expected approximately total charges charges approximately million recognized actions fourth quarter primarily resulting certain rd employee workforce reductions accelerated depreciation expected early site exits restructuring charges recognized upon meeting certain criteria including finalization committed plans reliable estimates discussions local works councils certain markets restructuring charges recognized prior actions primarily related specialty care transformation initiatives designed create simplified organization across functions geographic markets addition accelerated depreciation charges incurred connection early exits manufacturing site ireland rd site us employee termination benefit costs incurred manufacturing selling administrative rd employee workforce reductions across geographic regions approximately bristolmyers squibb following tables summarize charges activity related restructuring actions year ended december dollars millions employee termination costs termination costs provision restructuring accelerated depreciation asset impairments shutdown costs total charges year ended december dollars millions cost products sold research development incomeexpense total charges year ended december dollars millions liability january charges change estimates provision restructuring foreign currency translation spending liability december note income taxes provisionbenefit income taxes consisted year ended december dollars millions current us nonus total current deferred us nonus total deferred total provision annual report effective tax rate reconciliation effective taxbenefit rate us statutory federal income tax rate earnings income taxes dollars millions earningsloss income taxes us nonus total us statutory rate foreign tax effect certain operations ireland puerto rico switzerland us tax effect capital losses us federal valuation allowance release us federal state foreign contingent tax matters us federal research based credits goodwill allocated divestitures us branded prescription drug fee rd charges puerto rico excise tax domestic manufacturing deduction state local taxes net valuation allowance foreign effective tax rate lower us statutory rate primarily attributable undistributed earnings certain foreign subsidiaries considered expected indefinitely reinvested offshore us taxes provided approximately billion undistributed earnings foreign subsidiaries december undistributed earnings primarily relate operations switzerland ireland puerto rico undistributed earnings repatriated us future determined earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes provided bms operates favorable tax grant puerto rico scheduled expire prior divestiture certain businesses resulted capital loss tax benefits including million sale amylin shares valuation allowances attributed capital loss carryforwards released following divestiture recothrom ixempra mature brands additional reserves million established certain transfer pricing matters related tax periods orphan drug credits included us federal research based credits periods presented goodwill allocated business divestitures including diabetes business deductible tax purposes well us branded prescription drug fee periods rd charges resulting primarily milestone payment former shareholders flexus acquisitions padlock cormorant flexus cardioxyl ipierian also deductible tax purposes puerto rico imposes excise tax gross company purchase price goods sold manufacturer puerto rico excise tax recognized cost products sold intraentity sale occurs us income tax purposes excise tax deductible results foreign tax credits generally recognized provision income taxes excise tax incurred increased manufacturing activities opdivo resulted higher domestic manufacturing deduction bristolmyers squibb deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions deferred tax assets foreign net operating loss carryforwards us capital loss carryforwards state net operating loss credit carryforwards us federal net operating loss credit carryforwards deferred income milestone payments license fees pension postretirement benefits intercompany profit inventory items foreign deferred tax assets sharebased compensation legal settlements repatriation foreign earnings internal transfer intellectual property total deferred tax assets valuation allowance deferred tax assets net valuation allowance deferred tax liabilities depreciation acquired intangible assets goodwill total deferred tax liabilities deferred tax assets net recognized deferred income taxes noncurrent income taxes payable noncurrent total internal transfers intellectual property resulted deferred tax assets included prepaid taxes million december million prepaid taxes december assets amortized expected lives refer recently issued accounting standards note accounting policies information regarding impact amended guidance company expects adopt us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives december valuation allowance million established following items million primarily foreign net operating loss tax credit carryforwards million state deferred tax assets including net operating loss tax credit carryforwards million us federal net operating loss carryforwards million us federal deferred tax assets annual report changes valuation allowance follows year ended december dollars millions balance beginning year provision utilization foreign currency translation acquisitions balance end year income tax payments million million million current tax benefit realized result stock related compensation credited capital excess par value stock million million million business conducted various countries throughout world subject tax numerous jurisdictions significant number tax returns filed subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported requiring several years resolve liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation reconciliation beginning ending amount gross unrecognized tax benefits follows year ended december dollars millions balance beginning year gross additions tax positions related current year gross additions tax positions related prior years gross additions tax positions assumed acquisitions gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance end year additional information regarding unrecognized tax benefits follows year ended december dollars millions unrecognized tax benefits recognized would impact effective tax rate accrued interest accrued penalties interest expense penalty expensebenefit accrued interest penalties payable unrecognized tax benefits included either current noncurrent income taxes payable interest penalties related unrecognized tax benefits included income tax expense bms currently examination number tax authorities including limited major tax jurisdictions listed table proposed considering proposing material adjustments tax issues transfer pricing certain tax credits deductibility certain expenses bms estimates reasonably possible total amount unrecognized tax benefits december decrease range approximately million million next twelve months result settlement certain tax audits events expected change unrecognized tax benefits primarily settlement related involve payment additional taxes adjustment certain deferred taxes andor recognition tax benefits reasonably possible new issues raised tax authorities may increase unrecognized tax benefits however estimate increases reasonably made time bms believes adequately provided open tax years tax jurisdiction bristolmyers squibb following summary major tax jurisdictions tax authorities may assert additional taxes based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico note earnings per share year ended december amounts millions except per share data net earnings attributable bms used basic diluted eps calculation weightedaverage common shares outstanding basic contingently convertible debt common stock equivalents incremental shares attributable sharebased compensation plans weightedaverage common shares outstanding diluted earnings per share basic earnings per share diluted note financial instruments fair value measurements financial instruments include cash cash equivalents marketable securities accounts receivable payable debt instruments derivatives changes exchange rates interest rates create exposure market risk certain derivative financial instruments used available costeffective basis hedge underlying economic exposure instruments qualify cash flow net investment fair value hedges upon meeting certain criteria including effectiveness offsetting hedged exposures changes fair value derivatives qualify hedge accounting recognized earnings occur derivative financial instruments used trading purposes financial instruments subject counterparty credit risk considered part overall fair value measurement counterparty credit risk monitored ongoing basis mitigated limiting amounts outstanding individual counterparty utilizing conventional derivative financial instruments entering agreements counterparties meet high credit quality standards consolidated financial statements would materially impacted counterparty failed perform according terms agreement collateral required party whether derivatives asset liability position terms agreements fair value measurements fair value financial instruments classified one following categories level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets additionally certain corporate debt securities utilize thirdparty matrix pricing model using significant inputs corroborated market data substantially full term assets equity fixed income funds primarily invested publicly traded securities valued respective net asset value underlying investments level derivative instruments valued using libor yield curves less credit valuation adjustments observable forward foreign exchange rates reporting date valuations derivative contracts may fluctuate considerably volatility underlying foreign currencies underlying interest rates driven market conditions duration contract level unobservable inputs used little market data available level financial assets liabilities december annual report financial assets liabilities measured fair value recurring basis summarized december december dollars millions level level level level cash cash equivalents money market securities marketable securities certificates deposit commercial paper corporate debt securities equity funds fixed income funds derivative assets equity investments derivative liabilities availableforsale securities following table summarizes availableforsale securities gross gross unrealized unrealized gain loss amortized accumulated accumulated dollars millions cost oci oci fair value december certificates deposit commercial paper corporate debt securities equity investments total december certificates deposit corporate debt securities equity investments total december december dollars millions current marketable securitiesa noncurrent marketable securitiesb assets total fair value option financial assets elected investments equity fixed income funds fair value investments million december million december included current marketable securities changes fair value significant b noncurrent marketable securities mature within five years december bristolmyers squibb qualifying hedges following summarizes fair value outstanding derivatives december december dollars millions balance sheet location notional fair value notional fair value derivatives designated hedging instruments interest rate swap contracts prepaid expenses interest rate swap contracts assets interest rate swap contracts accrued liabilities interest rate swap contracts pension liabilities forward starting interest rate swap contracts prepaid expenses forward starting interest rate swap contracts assets forward starting interest rate swap contracts accrued liabilities forward starting interest rate swap contracts pension liabilities foreign currency forward contracts prepaid expenses foreign currency forward contracts accrued liabilities derivatives designated hedging instruments foreign currency forward contracts prepaid expenses foreign currency forward contracts accrued liabilities foreign currency forward contracts pension liabilities cash flow hedges foreign currency forward contracts used hedge certain forecasted intercompany inventory purchase transactions certain foreign currency transactions effective portion changes fair value contracts designated cash flow hedges temporarily reported accumulated comprehensive loss included earnings hedged item affects earnings net gains foreign currency forward contracts expected reclassified net earnings primarily included cost products sold within next two years notional amount outstanding foreign currency forward contracts primarily attributed euro million japanese yen million december bms entered million forward starting interest rate swap contracts maturing march hedge variability probable forecasted interest expense associated potential future issuances debt contracts designated cash flow hedges effective portion fair value changes included comprehensive income earnings impact related discontinued cash flow hedges hedge ineffectiveness significant periods presented cash flow hedge accounting discontinued forecasted transaction longer probable occurring within days originally forecasted date hedge longer effective assessments determine whether derivatives designated qualifying hedges highly effective offsetting changes cash flows hedged items performed inception quarterly basis net investment hedges nonus dollar borrowings million million december designated hedge foreign currency exposures net investment certain foreign affiliates borrowings designated net investment hedges recognized long term debt effective portion foreign exchange gains remeasurement euro debt million million million respectively recorded foreign currency translation component accumulated comprehensive loss related offset longterm debt fair value hedges fixedtofloating interest rate swap contracts designated fair value hedges used interest rate risk management strategy create appropriate balance fixed floating rate debt contracts underlying debt hedged benchmark risk recorded fair value effective interest rate contracts onemonth libor december plus interest rate spread ranging underlying swap terminated prior maturity fair value basis adjustment underlying debt instrument amortized reduction interest expense remaining life debt notional amount fixedtofloating interest rate swap contracts executed million million notional amount fixedtofloating interest rate swap contracts terminated million million million generating proceeds million million million including accrued interest additional contracts terminated connection debt redemptions annual report debt obligations shortterm borrowings current portion longterm debt includes december dollars millions bank drafts shortterm borrowings current portion longterm debt total average amount commercial paper outstanding million weightedaverage interest rate maximum month end amount commercial paper outstanding million outstanding borrowings december commercial paper borrowings longterm debt current portion longterm debt includes december dollars millions principal value notes due notes due notes due notes due notes due euro notes due notes due euro notes due notes due notes due notes due notes due notes due maturing subtotal adjustments principal value fair value interest rate swap contracts unamortized basis adjustment swap terminations unamortized bond discounts issuance costs total current portion longterm debt longterm debt fair value longterm debt million million december respectively estimated using level inputs based upon quoted market prices similar debt instruments fair value short term borrowings approximates carrying value due short maturities debt instruments bristolmyers squibb senior unsecured notes issued registered public offerings notes rank equally right payment bms 's existing future senior unsecured indebtedness redeemable whole part time predetermined redemption price bms also terminated forward starting interest rate swap contracts entered resulting unrealized loss comprehensive income following table summarizes issuance longterm debt obligations none amounts millions euro us dollars principal value euro notes due euro notes due total proceeds net discount deferred loan issuance costs forward starting interest rate swap contracts terminated notional amount unrealized loss following summarizes debt redemption activity none dollars millions principal amount carrying value debt redemption price notional amount interest rate swap contracts terminated interest rate swap termination payments loss debt redemptiona including acceleration debt issuance costs loss interest rate lock contract related fees interest payments million million million net amounts received interest rate swap contracts currently two separate billion revolving credit facilities syndicate lenders facilities provide customary terms conditions financial covenants extended october july facility extendable annually one year anniversary date consent lenders borrowings outstanding either revolving credit facility december available financial guarantees provided form standby letters credit performance bonds million december standby letters credit issued financial institutions support guarantees various obligations performance bonds issued support range ongoing operating activities including sale products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority outstanding financial guarantees expire within year expected funded annual report note receivables december dollars millions trade receivables less chargebacks cash discounts less bad debt allowances net trade receivables alliance receivables prepaid refundable income taxes receivables nonus receivables sold nonrecourse basis million million million aggregate receivables three pharmaceutical wholesalers us represented total trade receivables december respectively changes allowances bad debt chargebacks cash discounts follows year ended december dollars millions balance beginning year provision utilization balance end year note inventories december dollars millions finished goods work process raw packaging materials inventories inventories assets assets include inventory pending regulatory approval million december million december amounts expected remain onhand beyond one year bristolmyers squibb note property plant equipment leases december dollars millions land buildings machinery equipment fixtures construction progress gross property plant equipment less accumulated depreciation property plant equipment depreciation expense million million million annual minimum rental commitments noncancelable operating leases primarily real estate motor vehicles approximately million next five years aggregate million thereafter operating lease expense approximately million million sublease income capital lease obligations material periods presented note goodwill intangible assets december estimated dollars millions useful lives goodwill intangible assets licenses years developed technology rights years capitalized software years iprd gross intangible assets less accumulated amortization total intangible assets amortization expense intangible assets million million million future annual amortization expense intangible assets expected approximately million million million million million intangible asset impairment charges million million million million iprd impairment charge recognized bms lpa antagonist phase ii development treatment ipf full writeoff required considering occurrence certain adverse events voluntary suspension study internal assessment indicating significantly lower likelihood regulatory commercial success bms acquired bms acquisition amira pharmaceuticals inc addition contingent consideration liability million related acquisition also reversed lower likelihood success million iprd impairment charge recognized peginterferon lambda phase iii development treatment hcv full writeoff required assessing potential commercial viability asset estimating fair value assessment considered lower likelihood filing registration certain markets completing revised projections revenues expenses significant decline prior projected revenues resulted global introduction oral noninterferon products used treat patients hcv alternative uses product annual report note accrued liabilities december dollars millions accrued rebates returns employee compensation benefits accrued research development dividends payable royalties branded prescription drug fee restructuring pension postretirement benefits litigation settlements total accrued liabilities note equity common stock capital accumulated treasury stock excess par value comprehensive retained noncontrolling dollars shares millions shares par value stock loss earnings shares cost interest balance january net earnings comprehensive loss cash dividends stock compensation debt conversion variable interest entity distributions balance december net earnings comprehensive loss cash dividends stock compensation debt conversion distributions balance december net earnings comprehensive loss cash dividends stock repurchase program stock compensation distributions balance december treasury stock recognized cost reacquire shares shares issued treasury recognized utilizing firstin firstout method october board directors approved new share repurchase program authorizing repurchase additional billion common stock repurchases may made either open market private transactions including repurchase plans established accordance rule b securities exchange act stock repurchase program expiration date may suspended discontinued time bristolmyers squibb february bms entered asr agreements goldman sachs co morgan stanley co llc repurchase approximately billion common stock aggregate asr funded combination debt cash part existing share repurchase authorization total number shares ultimately repurchased asr determined upon final settlement based discount volumeweighted average price bms 's common stock asr period expected completed june components comprehensive incomeloss follows year ended december dollars millions pretax tax tax pretax tax tax pretax tax tax derivatives qualifying cash flow hedgesa unrealized gainslosses reclassified net earnings derivatives qualifying cash flow hedges pension postretirement benefits actuarial losses amortizationb settlements curtailmentsc pension postretirement benefits availableforsale securities unrealized gainslosses realized gainslossesc availableforsale securities foreign currency translation total comprehensive incomeloss included cost products sold b included cost products sold research development marketing selling administrative expenses c included incomeexpense accumulated balances related component comprehensive loss net taxes follows december dollars millions derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation accumulated comprehensive loss note pension postretirement benefit plans bms sponsors defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan covering us employees representing approximately consolidated pension plan assets obligations future benefits related service plan eliminated bms contributes least minimum amount required erisa plan benefits based primarily participants years credited service final average compensation plan assets consist principally equity fixed income securities annual report net periodic benefit costcredit defined benefit pension plans includes dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service credits amortization net actuarial loss curtailments settlements special termination benefits net periodic benefit costcredit september bms fiduciary counselors inc independent fiduciary bristolmyers squibb company retirement income plan entered definitive agreement transfer certain us pension assets prudential settle approximately billion pension obligations bms purchased group annuity contract prudential december irrevocably assumed obligation make future annuity payments certain bms retirees transaction change amount monthly pension benefit received affected retirees surviving beneficiaries resulted pretax settlement charge million pension settlement charges also recognized determining annual lump sum payments exceed annual interest service costs certain pension plans including primary us pension plan changes defined benefit pension plan obligations assets funded status amounts recognized consolidated balance sheets follows dollars millions benefit obligations beginning year service costbenefits earned year interest cost settlements actuarial gainslosses benefits paid foreign currency benefit obligations end year fair value plan assets beginning year actual return plan assets employer contributions settlements benefits paid foreign currency fair value plan assets end year funded status assetsliabilities recognized assets accrued liabilities pension liabilities funded status recognized accumulated comprehensive loss net actuarial losses prior service credit total accumulated benefit obligation defined benefit pension plans million million december respectively bristolmyers squibb additional information related pension plans follows dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets actuarial assumptions weightedaverage assumptions used determine defined benefit pension plan obligations december follows discount rate rate compensation increase weightedaverage actuarial assumptions used determine defined benefit pension plan net periodic benefit creditcost years ended december follows discount rate expected longterm return plan assets rate compensation increase yield high quality corporate bonds matching duration benefit obligations used determining discount rate citi pension discount curve used developing discount rate us plans expected return plan assets determined using expected rate return calculated value assets referred marketrelated value approximated fair value plan assets december differences assumed actual returns amortized marketrelated value straightline basis threeyear period several factors considered developing expected return plan assets including longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example priceearnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualized returns us pension plans follows years years years actuarial gains losses resulted changes actuarial assumptions changes discount rate revised mortality rates differences assumed actual experience differences actual expected return plan assets gains losses amortized life expectancy plan participants us plans years expected remaining service periods plans extent exceed higher marketrelated value projected benefit obligation respective plan amortization net actuarial loss prior service credit expected approximately million periodic benefit cost credit included cost products sold research development marketing selling administrative expenses except curtailments settlements special termination benefits included expenses annual report postretirement benefit plans comprehensive medical group life benefits provided substantially us retirees electing participate comprehensive medical group life plans lesser extent certain benefits nonus employees medical plan contributory contributions adjusted periodically vary date retirement life insurance plan noncontributory plan assets consist principally equity fixedincome securities postretirement benefit plan obligations million million december respectively fair value plan assets million million december respectively weightedaverage discount rate used determine benefit obligations december net periodic benefit credits material plan assets fair value pension postretirement plan assets asset category december follows december december dollars millions level level level total level level level total plan assets equity securities equity funds fixed income funds corporate debt securities us treasury agency securities shortterm investment funds insurance contracts cash cash equivalents plan assets subject leveling plan assets measured nav practical expedient equity funds venture capital limited partnerships total plan assets measured nav practical expedient net plan assets investment valuation policies per investment class follows level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs instruments include equity securities equity funds fixed income funds publicly traded national securities exchange cash cash equivalents cash cash equivalents highly liquid investments original maturities three months less time purchase recognized cost approximates fair value pending trade sales purchases included cash cash equivalents final settlement level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets observable inputs corroborated market data substantially full term assets liabilities equity funds fixed income funds shortterm investment funds classified level within fair value hierarchy valued net asset value shares held year end represents fair value corporate debt securities us treasury agency securities classified level within fair value hierarchy valued utilizing observable prices similar instruments quoted prices identical similar instruments markets active level unobservable inputs used little market data available insurance contracts held certain foreign pension plans carried contract value approximates estimated fair value based fair value underlying investment insurance company may fasb issued amended guidance removing requirement categorize within fair value hierarchy investments fair value measured using nav per share equivalent practical expedient guidance applied retrospectively table venture capital limited partnership investments typically redeemable distributions upon liquidation underlying assets significant unfunded commitments investments essentially liquidations expected occur remaining investments using practical expedient redeemable weekly monthly basis bristolmyers squibb following summarizes activity financial assets utilizing level fair value measurements dollars millions insurance contracts fair value january purchases sales settlements net realized losses fair value december purchases sales settlements net fair value december investment strategy maximize return maintaining appropriate level risk provide sufficient liquidity benefit obligations plan expenses target asset allocation public equity international global us private equity longduration fixed income maintained us pension plans investments diversified within three major asset categories approximately us pension plans equity investments actively managed bms common stock represents less plan assets december contributions estimated future benefit payments contributions pension plans million million million expected approximately million estimated annual future benefit payments including lump sum payments range approximately million million next five years aggregate billion subsequent five year period savings plans principal defined contribution plan bristolmyers squibb savings investment program contribution based employee contributions level company match expense attributed defined contribution plans us approximately million note employee stock benefit plans may shareholders approved plan replaced stock incentive plan plan provides million shares authorized grants plus shares outstanding awards plan february expire forfeited canceled withheld satisfy tax withholding obligations december million shares available award shares issued treasury stock satisfy obligations plan executive officers key employees may granted options purchase common stock less market price date option granted options generally become exercisable ratably four years maximum term ten years plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price company granted stock options stock appreciation rights since restricted stock units may granted key employees subject restrictions continuous employment generally vesting occurs ratably four year period grant date stock unit right receive stock end specified vesting period voting rights market share units granted executives vesting conditioned upon continuous employment vesting date payout factor least share price award date payout factor share price vesting date divided share price award date maximum share price used payout factor calculated using average closing prices grant vest date nine trading days immediately preceding grant vest date vesting occurs ratably four years performance share units granted executives three year cycle granted target number units subject adjustment number shares issued performance share units vest determined based achievement performance goals based company 's threeyear total shareholder return relative peer group companies vesting conditioned upon continuous employment occurs third anniversary grant date annual report stockbased compensation expense awards ultimately expected vest recognized vesting period forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates information related stockbased compensation benefits follows years ended december dollars millions restricted stock units market share units performance share units total stockbased compensation expense income tax benefit stock options restricted stock units market share units performance share units weighted number weighted number weighted number weighted number average average average average options exercise price nonvested grantdate nonvested grantdate nonvested grantdate shares thousands outstanding shares awards fair value awards fair value awards fair value balance january granted releasedexercised adjustments actual payout forfeitedcanceled balance december vested expected vest restricted market performance dollars millions stock units share units share units unrecognized compensation cost expected weightedaverage period years compensation cost recognized amounts millions except per share data weightedaverage grant date fair value per share restricted stock units market share units performance share units fair value awards vested restricted stock units market share units performance share units total intrinsic value stock options exercised fair value restricted stock units market share units performance share units approximates closing trading price bms 's common stock grant date adjusting units eligible accrued dividends addition fair value market share units performance share units considers probability satisfying payout factor total shareholder return respectively bristolmyers squibb following table summarizes significant ranges outstanding exercisable options december options outstanding exercisable number weightedaverage weightedaverage aggregate outstanding exercisable remaining contractual exercise price intrinsic value range exercise prices thousands life years per share millions aggregate intrinsic value preceding table represents total pretax intrinsic value based closing stock price december note legal proceedings contingencies company certain subsidiaries involved various lawsuits claims government investigations legal proceedings arise ordinary course business claims proceedings involve various types parties including governments competitors customers suppliers service providers licensees employees shareholders among others resolution matters often develops long period time expectations change result new findings rulings appeals settlement arrangements company recognizes accruals contingencies probable liability incurred amount loss reasonably estimated matters involve patent infringement antitrust securities pricing sales marketing practices environmental commercial contractual rights licensing obligations health safety matters consumer fraud employment matters product liability insurance coverage legal proceedings material company believes could become material described although company believes substantial defenses matters assurance increase scope pending matters future lawsuits claims government investigations legal proceedings material unless otherwise noted company unable assess outcome respective litigation able provide estimated range potential loss furthermore failure enforce patent rights would likely result substantial decreases respective product revenues generic competition intellectual property plavix australia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex inc apotex since changed name apotex august apotex filed application federal court australia federal court seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september federal court granted sanofis injunction subsidiary company subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated apotex case trial occurred april august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid company sanofi filed notices appeal full court federal court australia full court appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims stayed federal courts ruling apotex filed notice appeal appealing holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims hearing appeals occurred february september full court held claims patent invalid november company sanofi applied high court australia high court special leave appeal judgment full court march high court denied company sanofis request hear appeal full court decision case remanded federal court proceedings related damages sought apotex australian government intervened matter also seeking damages alleged losses experienced period injunction place company apotex settled apotex case case dismissed australian government 's claim still pending trial scheduled august possible time predict outcome australian governments claim impact company annual report sprycel european union may apotex actavis group ptc ehf generics uk limited mylan unnamed company filed oppositions european patent office epo seeking revocation european patent patent covering dasatinib active ingredient sprycel patent scheduled expire april excluding potential term extensions january opposition division epo revoked patent may company appealed epos decision epo board appeal february epo board appeal upheld opposition division 's decision patent revoked orphan drug exclusivity data exclusivity sprycel eu expired november epo board appeal 's decision affect validity sprycel patents within outside europe including different patents cover monohydrate form dasatinib use dasatinib treat chronic myelogenous leukemia cml additionally february epo board appeal reversed remanded invalidity decision european patent claim use dasatinib treat cml epo 's opposition division revoked october company intends take appropriate legal actions protect sprycel may experience decline european revenues event generic dasatinib product enters market antipd antibody patent oppositions litigation january bms ono announced companies signed global patent license agreement merck settle patentinfringement litigation related mercks pd antibody keytruda pembrolizumab agreement result dismissal prejudice patent litigation companies pertaining keytruda bms ono asserted litigation mercks sale keytruda infringed companies patents relating use pd antibodies treat cancer us europe uk netherlands france germany ireland spain switzerland australia japan part agreement merck make initial payment million bms ono merck also obligated pay ongoing royalties global sales keytruda january december january december agreement companies also granted certain rights respective patent portfolios pertaining pd initial payment royalties shared bms ono percent allocation respectively adjusting parties incurred legal fees september danafarber cancer institute danafarber filed complaint massachusetts federal court seeking correct inventorship five related us patents directed methods treating cancer using pd antibody specifically danafarber seeking add two scientists inventors patents pricing sales promotional practices litigation plavix state attorneys general lawsuits company certain affiliates sanofi defendants consumer protection andor false advertising actions brought several states relating sales promotion plavix possible time reasonably assess outcome lawsuits potential impact company product liability litigation company party various product liability lawsuits plaintiffs cases seek damages relief various grounds alleged personal injury economic loss previously disclosed addition lawsuits company also faces unfiled claims involving products plavix previously disclosed company certain affiliates sanofi defendants number individual lawsuits various state federal courts claiming personal injury damage allegedly sustained using plavix currently claims involving injury plaintiffs well claims spouses andor beneficiaries filed state federal courts various states including california new jersey delaware new york february judicial panel multidistrict litigation granted company sanofis motion establish multidistrict litigation mdl coordinate federal pretrial proceedings plavix product liability related cases new jersey federal court possible time reasonably assess outcome lawsuits potential impact company bristolmyers squibb byetta amylin former subsidiary company lilly codefendants product liability litigation related byetta date separate lawsuits pending behalf approximately active plaintiffs including pending settlements include injury plaintiffs well claims spouses andor beneficiaries various courts us company agreed principle resolve claims majority cases brought individuals allege personal injury sustained using byetta primarily pancreatic cancer pancreatitis cases claiming alleged wrongful death majority cases pending federal court san diego mdl coordinated proceeding california superior court los angeles jccp november defendants ' motion summary judgment based federal preemption granted mdl jccp plaintiffs mdl appealed us court appeals ninth circuit jccp plaintiffs appealed california court appeal amylin product liability insurance covering substantial number claims involving byetta additional liability amylin respect byetta expected shared company astrazeneca possible reasonably predict outcome lawsuit claim proceeding potential impact company abilify company otsuka codefendants product liability litigation related abilify plaintiffs allege abilify caused engage compulsive gambling impulse control disorders approximately cases filed state federal courts several additional cases pending canada judicial panel multidistrict litigation consolidated federal court cases pretrial purposes united states district court northern district florida eliquis company pfizer codefendants product liability litigation related eliquis plaintiffs assert claims including claims wrongful death result bleeding allege caused use eliquis cases filed state federal courts united states two cases filed canada judicial panel multidistrict litigation consolidated federal court cases pretrial purposes united states district court southern district new york shareholder derivative litigation since december three shareholder derivative lawsuits filed new york state court certain officers directors company plaintiffs allege among things breaches fiduciary duty surrounding companys previously disclosed october civil settlement securities exchange commission alleged foreign corrupt practices act violations china company agreed payment approximately million disgorgement penalties interest may company filed motions dismiss two shareholder derivative lawsuits government investigations like pharmaceutical companies company certain subsidiaries subject extensive regulation national state local government agencies us countries bms operates result company time time subject various governmental inquiries investigations possible criminal charges substantial fines andor civil penalties could result government investigations significant investigations conducted government agencies company aware listed abilify state attorneys general investigation march company received letter delaware attorney generals office advising multistate coalition coalition investigating whether certain abilify marketing practices violated respective states consumer protection statutes company executive committee coalition reached settlement matter one states new mexico members coalition participating settlement consent decrees entered participating states december environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties annual report cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency counterpart state foreign agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable company estimated share future costs sites million december represents sum best estimates best estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties million includes estimated costs additional probable loss associated previously disclosed north brunswick township high school remediation site note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earnings net earnings attributable noncontrolling interest bms earnings per share basica earnings per share diluteda cash dividends declared per common share cash cash equivalents marketable securitiesb total assets longterm debtc equity dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earningsloss net earningsloss attributable noncontrolling interest bms earningsloss per share basica earningsloss per share diluteda cash dividends declared per common share cash cash equivalents marketable securitiesb total assets longterm debt equity earnings per share quarters may add amounts year period computed discrete basis b marketable securities includes current noncurrent assets c longterm debt includes current portion bristolmyers squibb following specified items affected comparability results first second third fourth dollars millions quarter quarter quarter quarter year cost products solda license asset acquisition charges iprd impairments accelerated depreciation research development provision restructuring litigation settlements divestiture gains royalties licensing income pension charges intangible asset impairment incomeexpense increasedecrease pretax income income tax items increasedecrease net earnings specified items cost products sold accelerated depreciation asset impairment shutdown costs first second third fourth dollars millions quarter quarter quarter quarter year cost products solda marketing selling administrativeb license asset acquisition charges iprd impairments accelerated depreciation research development provision restructuring litigation settlements divestiture gainslosses pension charges intangible asset impairment written option adjustment loss debt redemption incomeexpense increasedecrease pretax income income tax items increasedecrease net earnings specified items cost products sold accelerated depreciation asset impairment shutdown costs b specified items marketing selling administrative process standardization implementation costs annual report reports management managements responsibility financial statements management responsible preparation integrity financial information presented annual report accompanying consolidated financial statements prepared conformity united states generally accepted accounting principles applying certain estimates judgments required managements opinion consolidated financial statements present fairly companys financial position results operations cash flows audit committee board directors meets regularly internal auditors deloitte touche llp dt companys independent registered accounting firm management review accounting internal control structure financial reporting matters internal auditors dt full free access audit committee set forth companys standard business conduct ethics company firmly committed adhering highest standards moral ethical behavior business activities managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report issued report effectiveness companys internal control financial reporting december included herein giovanni caforio chief executive officer charles bancroft chief financial officer february bristolmyers squibb controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule ae based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes company 's internal control financial reporting quarter ended december materially affected reasonable likely materially affect company 's internal control financial reporting information none annual report report independent registered public accounting firm board directors shareholders bristolmyers squibb company audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income cash flows three years period ended december financial statements responsibility companys management responsibility express opinion financial statements based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also audited accordance standards public company accounting oversight board united states companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion companys internal control financial reporting parsippany new jersey february bristolmyers squibb report independent registered public accounting firm board directors shareholders bristolmyers squibb company audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion company maintained material respects effective internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements year ended december company report dated february expressed unqualified opinion consolidated financial statements parsippany new jersey february annual report performance graph following performance graph compares performance bristolmyers squibb periods indicated performance standard poors stock index sp average performance group consisting peer corporations line ofbusiness basis corporations making peer group abbvie inc amgen inc astrazeneca plc biogen inc celgene corp eli lilly company gilead sciences inc glaxosmithkline johnson johnson merck co inc novartis ag pfizer inc roche holding ltd sanofi total return indices reflect reinvested dividends weighted using beginningperiod market capitalization reported time periods bristolmyers squibb sp index peer group assumes invested bristolmyers squibb common stock sp index peer group values december specified year assuming dividends reinvested bristolmyers squibb fiveyear financial summary amounts millions except per share data income statement dataa total revenues continuing operations net earnings net earnings attributable noncontrolling interest bms net earnings per common share attributable bms basic diluted average common shares outstanding basic diluted cash dividends paid bms common preferred stock cash dividends declared per common share financial position data december cash cash equivalents marketable securitiesb total assets longterm debtb equity discussion items affected comparability results years refer item managements discussion analysis financial condition results operationsnongaap financial measures b includes current noncurrent portion annual report summary abbreviated terms bristolmyers squibb company may referred bristolmyers squibb bms company us annual report throughout annual report used terms defined annual report fiscal year ended december lilly eli lilly company abbvie abbvie inc maa marketing authorization application amira amira pharmaceuticals inc mcos managed care organizations amylin amylin pharmaceuticals inc mcrc metastatic colorectal cancer anda abbreviated new drug application mead johnson mead johnson nutrition company anticcp anticyclic citrullinated peptide also acpa medarex medarex inc api active pharmaceutical ingredient merck merck co inc asct autologous stem cell transplant mf myelofibrosis asr accelerated share repurchase msih high microsatellite instability astrazeneca astrazeneca plc mtx methotrexate autohsct autologous hematopoietic stem cell transplantation muc metastatic urothelial carcinoma bla biologics license application nav net asset value cardioxyl cardioxyl pharmaceuticals inc nda new drug application cdai clinical disease activity index nitto denko nitto denko corporation cercla us comprehensive environmental response compensation liability act nkt natural killer cells cgmp current good manufacturing practices novartis novartis pharmaceutical corporation chl classical hodgkin lymphoma nsclc nonsmall cell lung cancer chmp committee medicinal products human use nsq nonsquamous cormorant cormorant pharmaceuticals nvaf nonvalvular atrial fibrillation cppib cppib credit europe sarl luxembourg private limited liability company oci comprehensive income office inspector general us dept health csfr colony stimulating factor receptor oig human services dmc data monitoring committee ono ono pharmaceutical co ltd ebitda earnings interest taxes depreciation amortization orr objective response rate ec european commission otc overthecounter egfr epidermal growth factor receptor otsuka otsuka pharmaceutical co ltd ela excess loss account pad proteinpeptidyl arginine deiminase ema european medicines agency padlock padlock therapeutics inc epo european patent office pbms pharmacy benefit managers eps earnings per share pd programmed death receptor erisa employee retirement income security act pdma prescription drug marketing act eu european union pfizer pfizer inc fasb financial accounting standards board pfs progressionfree survival fcpa foreign corrupt practices act portola portola pharmaceuticals inc fda us food drug administration promedior promedior inc five prime five prime therapeutics inc prp potentially responsible party flexus flexus biosciences inc prudential prudential insurance company america fstar fstar alpha ltd psa prostatespecific antigen gaap us generally accepted accounting principles pvns pigmented vilonodular synovitis gdd genetically defined diseases rd research development gilead gilead sciences inc ra rheumatoid arthritis hcv hepatitis c virus ravs resistanceassociated variants hiv human immunodeficiency virus rcc renal cell carcinoma hr hazard ratio reckitt reckitt benckiser group plc hr patient protection affordable care act rf rheumatoid factor hsp heat shock protein scchn squamous cell carcinoma head neck imas inventory management agreements sclc small cell lung cancer imclone imclone systems incorporated sec us securities exchange commission io immunooncology sq squamous inhibitex inhibitex inc svr sustained virologic response ipf idiopathic pulmonary fibrosis plan stock award incentive plan ipierian ipierian inc us united states iprd inprocess research development uk united kingdom jmhlw japanese ministry health labour welfare valeant valeant pharmaceuticals international inc lda low disease activity vte venous thromboembolic libor london interbank offered rate wto world trade organization bristolmyers squibb board directors lamberto andreotti alan j lacy chairman board directors nonexecutive chairman bristolmyers squibb dave busters entertainment inc ab giovanni caforio md chief executive officer chairmandesignate thomas j lynch jr md bristolmyers squibb chairman chief executive officer massachusetts general physicians organization peter j arduini bd president chief executive officer integra lifesciences holdings corporation dinesh c paliwal chairman president chief executive officer harman international industries inc robert j bertolini ab former president chief financial officer bausch lomb theodore r samuels retired president capital guardian trust company matthew w emmens retired chief executive officer chairman vicki l sato phd shire plc professor management practice harvard business school laurie h glimcher md cd president ceo danafarber cancer institute principal investigator director danafarber gerald l storch harvard cancer center richard susan smith chief executive officer hudsons bay company professor medicine harvard medical school nonexecutive chairman supervalu inc ac michael grobstein togo west jr retired vice chairman ernst young llp chairman tli leadership group ac bc members board directors march eleven members elected may annual meeting audit committee b committee directors corporate governance c compensation management development committee science technology committee bristolmyers squibb leadership team giovanni caforio md ann powell judge chief executive officer senior vice president chief human resources officer charles bancroft executive vice president chief financial officer sandra leung head global business operations executive vice president general counsel emmanuel blin senior vice president chief strategy officer anne nielsen senior vice president chief compliance ethics officer francis cuss mb bchir frcp executive vice president chief scientific officer lou schmukler president global manufacturing supply john elicker senior vice president public affairs investor relations paul von autenried senior vice president chief information officer murdo gordon executive vice president chief commercial officer bristolmyers squibb stockholder information common stock product names company programs ticker symbol bmy free copy companys annual global products company program new york stock exchange report fiscal year names appearing throughout italics ended december contact referred herein registered annual meeting stockholders approved us trademarks unless corporate secretary specifically noted otherwise tuesday may bristolmyers squibb company bristolmyers squibb company park avenue abilify trademark otsuka princeton pike new york ny pharmaceutical co ltd lawrence township nj also available adcetris trademark seattle stockholder services investorbmscom genetics inc inquiries concerning stockholder recent certifications atripla trademark bristolmyers accounts stock transfer matters companys chief executive officer chief squibb gilead sciences llc financial officer pursuant section including address changes sarbanesoxley act filed avaproavalide known eu elimination duplicate mailings exhibits companys aprovelkarvea plavix shareowner services plus plansm company also filed new york trademarks sanofi directed companys stock exchange recent annual transfer agent registrar bydureon byetta symlin trade ceo certification required section marks amylin pharmaceuticals llc aa new york stock exchange wells fargo shareowner services listed company manual erbitux trademark imclone llc centre pointe curve suite mendota heights mn farxiga onglyza trademarks additional information astrazeneca ab wwwshareowneronlinecom information following subjects gleevec trademark novartis ag available wwwbmscom within us outside us bristolmyers squibb foundation ixempra trademark rpharm us operating llc telecommunications relay service clinical trials used hearing impaired compliance ethics keytruda trademark merck sharp calling telephone numbers diversity workforce statistics dohme corp shareowner services plus plansm patient assistance programs myalept trademark aegerion policy advocacy engagement pharmaceuticals inc shareowner services plus plansm political contributions designed longterm investors wish prostvac trademark bn build share ownership companys sustainabilityenvironmental programs immunotherapeutics inc common stock time partici annual report contains certain recothrom trademark pate plan registered holder forwardlooking information within medicines company companys common stock meaning private securities litigation companys common stock revlimid trademark celgene reform act forwardlooking become participant making corporation statements based current expectations initial purchase plan plan involve inherent risks uncertainties truvada tybost trademarks features dividend reinvestment optional could cause actual outcomes results gilead sciences inc andor one cash purchase share safekeeping differ materially current expectations affiliates share sales transfers bristolmyers please see financial review squibb company appointed wells fargo brand names products discussion description shareowner services administrator italicized letters without asterisk risks uncertainties company plan plan sponsored adminis registered trademarks bristolmyers undertakes obligation publicly update tered bristolmyers squibb company squibb andor one subsidiaries forwardlooking statement whether result new information future events otherwise shareowner services plus plan service mark wells fargo shareowner services callia baines managing physical emotional pain ra anyone diagnosed didnt really want tell anyone callia rheumatoid arthritis ra knows firsthand get says didnt want anyone pity pain swollen stiff joints finding answer aching muscles fatigue live life graduating college taking yearold callia baines fulltime job human resources im able live life terms maryland resident continued debilitating effects ra gratei fn uc l r fe od ri b thl ay symptoms ra still undiagnosed caused emotional pain often four years ago casual game overshadowed physical pain tugofwar dog inadvertently led answer didnt really life recalls callia began noticing symptoms ra teenager couldnt hang playing dog accidentally bit callias friends know normal things hand next morning woke discover hand swollen red went doctor ruled years callia family sought medical answers dog bite caused swelling ordered blood experiencing painful foot cramps spasms work test ra came back positive spread legs exhausted time symptoms drastically limited activity high finally diagnosis brought clarity callias world school college diagnosis wasnt immediate initial treatments manage ra didnt bring relief callia felt like left deal condition alone hoped thats physician prescribed orencia following treatment callia felt like regaining mobility one particular episode college callia called also experiencing less pain mom crying pain feet severe didnt know mom asked could get live life im incredibly grateful ask friends help callia says feel like bristolmyers squibb company rights reserved park avenue new york ny wwwbmscom facebook f logo cmyk ai facebook f logo cmyk ai